SHIKARI 抗体药，研发加速器！

Biological Drug Monitoring ELISA Kits

Product Catalog
6th Edition

Amylet Scientific
艾美捷科技

Matriks 中国区总代理，艾美捷科技，400-6800-868

"Shikari 生物药物监测 ELISA 试剂盒，在个性化药物的检测中，被广泛且安全的使用"

- Haluk Ataoğlu教授，MD，PhD

首席执行官

"Shikari® biological drug monitoring ELISA kits can personalize the usage of drugs and enables them to be used effectively and safely."

Prof. Haluk Ataoglu MD, PhD
CEO

MATRIKS BIOTEK

20 years experience
innovation for health & wellness

Matriks 中国区总代理，艾美捷科技，400-6800-868

目录

ABATACEPT，阿巴西普，Orencia®
ADALIMUMAB，阿达木单抗，Humira®
AFLIBERCEPT，阿柏西普，Eylea®
ATEZOLIZUMAB，阿替利珠单抗，Tecentriq®
AVELUMAB，阿维鲁单抗，Bavencio®
BEVACIZUMAB，贝伐珠单抗，Avastin®
CANAKINUMAB，卡那单抗，Ilaris®
CERTOLIZUMAB，塞妥珠单抗，Cimzia®
CETUXIMAB，西妥昔单抗，Erbitux®
DARATUMUMAB，达雷木单抗，Darzalex®
DENOSUMAB，地舒单抗，Prolia®
DURVALUMAB，度伐利尤单抗，Imfinzi®
ECULIZUMAB，依库珠单抗，Soliris®
ETANERCEPT，依那西普，Enbrel®
EVOLOCUMAB，依洛尤单抗，Repatha®
FILGRASTIM，非格司亭，Fraven®
GOLIMUMAB，戈利木单抗，Simponi®
INFLIXIMAB，英夫利昔单抗，Remicade®
INFLIXIMAB BIOSIMILAR，英夫利昔类似物，Remsima®
IPILIMUMAB，伊匹单抗，Yervoy®
IXEKIZUMAB，依奇珠单抗，Taltz®
NATALIZUMAB，那他珠单抗，Tysabri®
NIVOLUMAB，纳武单抗，Opdivo®
OMALIZUMAB，奥马珠单抗，Xolair®
PALIVIZUMAB，帕利珠单抗，Synagis®
PEMBROLIZUMAB，帕博利珠单抗，Keytruda®
PERTUZUMAB，帕妥珠单抗，Perjeta®
RAMUCIRUMAB，雷莫芦单抗，Cyramza®
RANIBIZUMAB，雷珠单抗，Lucentis®
RISANKIZUMAB，瑞莎珠单抗，Skyrizi®
RITUXIMAB，利妥昔单抗，Rituxan®, Mabthera®
SECUKINUMAB，司库奇尤单抗，Verxant®
TOCILIZUMAB，托珠单抗，Actemra®
TRASTUZUMAB，曲妥珠单抗，Herclon®, Herceptin®
USTEKINUMAB，乌司奴单抗，Stelara®
VEDOLIZUMAB，维多珠单抗，Entyvio®

Matriks Biotechnology®是一家生物技术公司，致力于生物技术研究，产品开发，并在全球范围内提供产品，帮助人们过上更好的生活。

Matriks Biotechnology是由Haluk Ataoğlu教授（微生物学和免疫学博士）于2002年创立的医学生物技术公司。他是一位学者出身的公司创始人兼首席执行官。该公司进行生命科学和生物技术研究，并在全球范围内开发和提供产品，以帮助人们过上更好的生活。该公司于2022年庆祝了其成立20周年。

Matriks Biotek®是全球首家生产和商业化生物药物监测ELISA试剂盒的公司，品牌名称为SHIKARI®，自2008年以来，通过其产品为大分子的治疗药物监测创造了一个世界市场。

根据该领域的已发表记录，测量接受药物治疗的患者的谷浓度水平能够帮助我们了解药物水平是否处于最佳剂量范围。如果剂量高于最佳剂量，可以调整给药间隔时间或减少剂量以达到最佳剂量。如果出现反应丧失（LOR），则谷浓度水平将低于有效剂量，在这种情况下，可以增加剂量，并使用抗药物抗体（ADA）检测来确定是否存在ADA，可能需要更换其他可用的生物药物。监测生物药物的使用可以使有价值的生物制品得到有效和安全的使用。积极的生物药物监测对于成本效益也具有巨大的重要性，在生物药物支出方面至少可以降低10%，因此对经济有着相当大的影响。此外，如果合理使用和成本效益是一个问题，提供与生物药物一起的测试可能会说服社会保障机构和政府。

在疫情爆发后，该公司进行了广泛的研究，并开发了市场上独特且信息丰富的16种CoronaHunter® ELISA试剂盒，这些试剂盒是最具信息量的。这些试剂盒可以测量新型冠状病毒的免疫球蛋白G、A、M和E的值，包括对STRIMER、Spike S1、Spike RBD和核衣壳蛋白的测量。准确测定免疫球蛋白G、A、M和E抗体浓度，以μg/ml表示，可以提供正确的信息，使测试结果能够持续和协调一致。IgE测量试剂盒是市场上唯一可以测量对新型冠状病毒蛋白质特异性过敏的试剂盒。所有试剂盒都经过验证，使用了来自国家生物标准与控制研究所（NIBSC，世界上主要的世界卫生组织国际标准和参考材料的生产和分发机构）的面板血清和其他各种血清。这是第一次测量并以μg/ml的"绝对"值表示国家生物标准与控制研究所的面板标准值，为比较提供了有价值的信息，并使结果能够协调一致。最近，使用CoronaHunter®COR-QNS-IGG-SRBD试剂盒，我们测量了世界卫生组织国际标准和参考材料的5个面板血清（20/268）的"绝对值"，并以μg/ml的形式给出结果，以便实验室之间进行比较和协调。https://www.linkedin.com/feed/update/urn:li:activity:6885241659429408768/

该公司在市场上拥有91种不同的ELISA试剂盒，用于36种生物药物的检测，以及16种不同的ELISA试剂盒，用于检测新型冠状病毒抗体，总共有106种产品。这些产品数量和品种在各自领域内是最多的，质量也是最高的，具有独特性。此外，我们在SHIKARI®品牌下还有一些新的试剂盒正在研发中，将在未来推出。已有超过160篇的科学论文使用了SHIKARI®和CoronaHunter®品牌的ELISA试剂盒。

Matriks Biotek®是世界上少有的一家将自身定位为研发公司的生物技术公司，通过进行持续的研发工作，直接销售产品或与合格的分销伙伴合作，使用自己的品牌或通过OEM协议销售产品，并将其营收的一半用于研发投资。生产工作由专业科学家按照ISO 13485:2016质量管理体系进行。该公司的所有产品均获得了欧洲CE-IVD标志。

公司的目标是专注于向全球出口产品。公司出口的产品超过95%销往四十多个国家，其中包括美国、欧盟、中国、韩国、以色列、沙特阿拉伯、日本、伊拉克、挪威、俄罗斯、加拿大、台湾、爱尔兰、英国、澳大利亚和新西兰等。该公司还向三十多家生产生物类似药物的制药公司提供了产品。我们的公司愿意与机构进行合作。

WHY SHIKARI® KITS?

- 每个试剂盒的动态测量范围都针对药物的Cmax-Cmin（谷浓度）进行了优化。此外，研究人员还可以测量人、小鼠、大鼠和猴子血清或血浆样品中药物的生物学水平，用于药代动力学研究。
- 已有超过160篇的科学论文使用了SHIKARI® ELISA试剂盒。
- 所有的SHIKARI® ELISA试剂盒都符合国际标准，并且易于发布结果。
- 提供了18种不同生物药物的抗药物抗体（免疫原性）定量ELISA试剂盒，并配备了确认试剂。Matriks Biotek®是第一家为Remsima®（Infliximab生物类似药物CT-P13）生产ELISA试剂盒的生物技术公司。Remsima®的试剂盒包括定量游离药物检测试剂盒、定性抗Remsima®检测试剂盒和Remsima®总抗体检测试剂盒。
- 开发了总抗体试剂盒，用于鉴定血清中与药物结合但无法通过游离抗体检测试剂盒确定的抗药物抗体。Matriks Biotek®为3种不同的药物开发了总抗体检测试剂盒：Infliximab（Remicade®，Remsima®）和Adalimumab（Humira®）。这些TOTAL试剂盒同时测量游离抗药物抗体，可以比较总抗体和游离抗药物抗体的结果，得到半定量结果。试剂盒在市场上是独一无二的。正在进行针对不同药物的总抗体检测试剂盒开发研究，请咨询。
- 定量ADA检测试剂盒包括确认试剂，以消除结果中的假阳性。市场上独一无二。
- 满足FDA和EMEA的要求的批内和批间变异系数（CV）。
- 高回收率（85-115%），
- 低样品体积（10-25µl），即使对于非常小的样品，如小鼠血清
- 所有液体和高度稳定的即用试剂。
- 配送在室温下进行。节省成本！
- 使用最高质量的材料。
- 微孔板 NUNC®，蛋白质的最小%CV的完美结合，与我们专有的阻断缓冲液完全匹配，几乎没有背景信号，保存期很长
- 塑料瓶 Nalgene®，非常耐用，具有完美的表面特性
- 玻璃小瓶 Schott® 用于标准容器；经过严格测试。与其他品牌相比，无蛋白质结合的透明玻璃瓶盖
- SHIKARI® ELISA试剂盒采用96孔板格式，每个试剂盒可以运行多达90个样品。
- 节省时间：生物制品测试的短孵育时间（70-140分钟）
- 1 年有效期
- 交货时间短
- 为您的特定生物类似药物或原创分子开发定制ELISA试剂盒的项目开发。
- 试剂盒适用于生物类似药物的研究。试剂盒采用重组人蛋白配体结合测定法。
- 无放射性
- 所有Shikari® ELISA试剂盒均在ISO 13485质量体系下生产，并获得CE IVD标志。


CERTIFICATE

MATRİKS BİYOTEKNOLOJİ SANAYİ VE TİCARET LİMİTED ŞİRKETİ

ISO 13485:2016

PRODUCTION, SALES AND STORAGE OF ELISA KITS

ELISA KİTLERİNİN ÜRETİMİ, SATIŞI VE DEPOLANMASI


MATRIKS BIOTEK

CERTIFICATE

EC DECLARATION OF CONFORMITY of MATRİKS BİYOTEKNOLOJİ SAN. ve TİC. LTD. ŞTİ.

CE

Matriks Biotek® is now cerified for quality management system ISO 13485:2016. All of the SHIKARI® products from Matriks Biotek® are marked with the CE IVD mark according to Council Directive 98 / 79 / EC relating to In Vitro Diagnostic Medical Device Directive.



生物治疗药物的免疫原性

免疫原性在生物药物的开发和治疗过程中被明确定义，但是它是一种不希望发生的情况。对生物治疗药物产生免疫反应会极大地影响产品的安全性和疗效。特别是，抗药物抗体（ADA）可以通过影响药物达到预期靶点的能力、改变药物的药代动力学特性，并潜在地引发严重的不良反应。

在使用生物治疗药物的患者中，免疫反应的临床效果具有高度的变异性，从完全没有效果到极具害的效果（如过敏反应、细胞因子释放综合征和对介导关键功能的内源性蛋白产生交叉反应中和）对患者的健康产生影响。

免疫原性反应通常包括细胞（T细胞）和体液（抗体）两个免疫反应分支，患者和药物本身的一些因素会影响对生物治疗药物的免疫原性。针对生物治疗药物的抗体（抗药物抗体，ADA）可能包括IgM、IgG、IgE和/或IgA亚型。

抗药物抗体的产生可能导致疗效降低和/或增加不良反应的风险（如输注反应、过敏反应或免疫复合物介导的疾病）。在罕见情况下，抗药物抗体的产生不仅针对于治疗用的生物治疗药物，还可能针对其内源性对应蛋白，如果内源性蛋白是独特的、不可替代的并具有重要的生命功能，可能引发危及生命的反应。鉴于这些可能性，监管机构要求在生物治疗药物的批准过程中评估其免疫原性，并确定其特性与任何引起的临床后果相对应。

药物耐受性的重要性

- 免疫原性检测通常以治疗药物为基石，通常通过固定药物的方式进行
- 通过在过量可溶性药物存在的情况下减少ADA结合来确认检测到的抗药物抗体的特异性
- 当患者血液中存在可溶性残留药物时，可形成循环免疫复合物
- 在ADA分析的患者血清样本中存在可溶性药物可能会抑制检测到抗药物抗体的检测。药物耐受性的定义
- 药物耐受性描述了在可溶性药物存在的情况下，您的抗药物抗体检测的敏感性
- 通过评估在添加递增量的可溶性药物的情况下的检测敏感性来确定耐受性。抗体反应的潜在影响安全考虑
- 对过敏反应的风险
- 对免疫复合物疾病的潜在风险

疗效考虑因素

- 抗体可能与药物结合并改变药物的药代动力学特性
- 抗体可能改变药物的生物分布
- 抗体可能与药物的活性位点结合（或靠近），从而抑制其活性
- 抗体可能以干扰药物与其受体或配体结合的方式结合



CLINICAL IMMUNOGENICITY

Risk of Clinical Sequelae
· "Binding" ADA
· PK-altering ADA
· Neutralizing ADA
· Hypersensitivity ADA
· Cross-Reactive Neutralizing ADA

The severity of Anti Drug Antibody (ADA) impact and its frequency of occurrence have been inversely correlated.

SHIKARI® ADA检测试剂盒用于检测抗药物抗体（ADA）

Matriks　Biotek®公司生产了几种不同格式的ADA检测试剂盒，用于免疫原性测量。在测量药物水平和ADA时的战略方法是在下一剂药物给药前的1-2天或刚刚给药后取样，此时药物的清除主要已经完成。

SHIKARI® ELISA检测试剂盒的测试格式：

• 筛查Free抗药物抗体的ELISA检测试剂盒

在这种测试格式中，板上涂覆有药物，并且该药物能够捕获与该药物相对应的抗药物抗体。同样的药物被标记上酶，并用于监测样品中的抗药物抗体（ADA）

• 定量Free抗药物抗体检测试剂盒：

在这种测试格式中，板上涂覆有药物，并且该药物能够捕获与该药物相对应的抗药物抗体。同样的药物被标记上酶，并用于监测样品中的抗药物抗体（ADA）。通过标准曲线进行定量，标准曲线由递减浓度的中和单克隆抗体组成，可以给出精确的结果。在测量ADA水平之后，可以使用"确认试剂"对样品进行确认，以区分。

• 半定量总/Free ADA, Free和总抗药物抗体ELISA检测试剂盒

该试剂盒可以在同一试剂盒和同一检测方案中同时测量自由和总抗药物抗体。样品可以直接用于测量自由ADA和/或先进行酸解离，然后测量总ADA。酸解离会破坏循环免疫复合物，并能够检测和测量与药物结合的ADA以及自由的ADA。因此，ADA测定具有较高的药物耐受性，可以提供有关发生的ADA和患者状态的更多信息。试剂盒包含阴性、阳性和免疫复合物标准，用于控制检测过程。

示例：SHIKARI® Q-ATI总/自由ADA半定量ELISA检测试剂盒

用于检测英夫利昔单抗（Remicade®）的总和自由抗药物抗体的SHIKARI® ELISA检测试剂盒

• 同一试剂盒可以同时检测"自由"和"总"抗药物抗体。
• 在总ATI的解离步骤后，该试剂盒使用与自由ATI相同的检测方案。
• 仅需要40µl的血清/血浆样品。
• 总孵育时间仅为1小时35分钟。
• 易于自动化适应。
• 包含反应性、阴性和免疫复合物（药物+中和抗体）控制。
• 最低检测限度：156 ngr/ml。

PRODUCTS

Matriks 中国区总代理，艾美捷科技，400-6800-868

ABATACEPT，阿巴西普
SHIKARI®

Q-ABA • S-ATAB • S-ATAB w/confirmation

ABATACEPT (Orencia®) ELISA

Abatacept is a disease-modifying antirheumatic drug (DMARD) used in the management of rheumatic conditions, such as rheumatoid or psoriatic arthritis, and for the prophylaxis of acute graft-versus-host disease. Abatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1). Abatacept is a selective costimulation modulator - like CTLA-4, the drug has shown to inhibit T-cell (T lymphocyte) activation by binding to CD80 and CD86, thereby blocking interaction with CD28. Blockade of this interaction has been shown to inhibit the delivery of the second co-stimulatory signal required for optimal activation of T-cells. This results in the inhibition of autoimmune T-Cell activation that has been implcated in the pathogenesis of rheumatoid arthritis. Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary.

SHIKARI® Q-ABA: Enzyme immunoassay for the quantitative determination of Abatacept (Orencia®) in serum and plasma. This kit has been especially developed for the quantitative determination of Abatacept in serum and plasma samples between the Cmin and Cmax range of concentrations.

Shikari® (Q-ABA) Abatacept ELISA



Catalog Number/Code	Q-ABA ABA-FD-ORE
Required Volume (µl)	10
Total Time (min)	105
Sample	Serum, plasma
Sample Number	96
Detection Limit (ng/ml)	3
Spike Recovery (%)	Between 85 - 115
Shelf Life (year)	1
Assay Type	Quantitative
Species Reactivity	Human
Storage Conditions	Store at +4°C. Please refer to protocols.
Shipping Conditions	At room temperature

ABATACEPT，阿巴西普
SHIKARI®

Q-ABA • S-ATAB • S-ATAB w/confirmation

ABATACEPT (Orencia®) ELISA

SHIKARI® S-ATAB: Enzyme immunoassay for the qualitative determination of specific antibodies to Abatacept (Orencia®) in serum and plasma. This kit has been especially developed for the qualitative determination of specific antibodies to Abatacept in serum and plasma samples.

SHIKARI® S-ATAB w/confirmation: Enzyme immunoassay for the quantitative determination of specific antibodies to Abatacept (Orencia®) in serum and plasma. This kit has been especially developed for the quantitative determination of specific antibodies to Abatacept in serum and plasma samples.

Shikari® (S-ATAB) Anti-Abatacept ELISA w/confirmation



	S-ATAB ABA-QLS-ORE	S-ATAB w/confirmation ABA-QNS-ORE
Catalog Number/Code		
Required Volume (µl)	20	20
Total Time (min)	140	140
Sample	Serum, plasma	Serum, plasma
Sample Number	96	96
Detection Limit (ng/ml)	+ / -	50
Spike Recovery (%)	-	Between 85 - 115
Shelf Life (year)	1	1
Assay Type	Qualitative	Quantitative
Species Reactivity	Human	Human
Storage Conditions	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.
Shipping Conditions	At room temperature	At room temperature

ADALIMUMAB，阿达木单抗
SHIKARI®

Q-ADA • QS-ADA • S-ATA • S-ATA w/confirmation • S-ATA (Free/Total Ab)

ADALIMUMAB (Humira®) ELISA

Adalimumab is a monoclonal anti-tumor necrosis factor alpha antibody used in the treatment of a wide variety of inflammatory conditions such as rheumatoid arthritis, Crohn's disease, and ankylosing spondylitis. Adalimumab binds with specificity to tumor necrosis factor-alpha (TNF-alpha) and inhibits its interaction with the p55 and p75 cell surface TNF receptors.

Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary.

SHIKARI® Q-ADA: Enzyme immunoassay for the quantitative determination of Adalimumab (Humira®) in serum and plasma. This kit has been especially developed for the quantitative determination of adalimumab in serum and plasma samples between the Cmin and Cmax range of concentrations.

SHIKARI® QS-ADA: Adalimumab ELISA has been especially developed for the specific and quantitative analysis of free adalimumab in serum and plasma samples.

Shikari® (Q-ADA) Adalimumab ELISA



Shikari® (QS-ADA) Adalimumab ELISA



Catalog Number/Code	**Q-ADA** ADA-FD-HUM	**QS-ADA** ADA-SPEC-ADA
Required Volume (µl)	20	20
Total Time (min)	70	70
Sample	Serum, plasma	Serum, plasma
Sample Number	96	96
Detection Limit (ng/ml)	10	18,75
Spike Recovery (%)	Between 85 - 115	-
Shelf Life (year)	1	1
Assay Type	Quantitative	Quantitative
Species Reactivity	Human	Human
Storage Conditions	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.
Shipping Conditions	At room temperature	At room temperature

ADALIMUMAB, 阿达木单抗 SHIKARI®

Q-ADA • QS-ADA • S-ATA • S-ATA w/confirmation • S-ATA (Free/Total Ab)

ADALIMUMAB (Humira®) ELISA

Demonstration of anti-adalimumab antibodies during treatment with Adalimumab (Humira®) has a major concern and monitoring for the presence and/or quantitation of specific antibodies during clinical trials is an important issue for follow up of the treatment regimens. With the Matriks Biotek® SHIKARI® S-ADA Total/Free ADA ELISA Kit adalimumabspecific antibodies that are bound to adalimumab in serum and cannot be detected by free antibody detection kits can be determined in patients receiving Humira®.

SHIKARI® S-ATA: Enzyme immunoassay for the qualitative antibodies to Adalimumab (Humira®) in serum and plasma samples. This kit has been especially developed for the qualitative antibodies to Adalimumab in serum and plasma samples.

SHIKARI® S-ATA w/confirmation: Enzyme immunoassay for the quantitative determination of antibodies to Adalimumab (Humira®) in serum and plasma with confirmation. This kit has been especially developed for the quantitative antibodies to Adalimumab in serum and plasma samples.

SHIKARI® S-ADA (Free/Total Ab): Enzyme immunoassay for the semi-quantitative determination (screening) of total and free antibodies to Adalimumab (Humira®) in serum and plasma.

Shikari® Anti-Adalimumab ELISA



Catalog Number/Code	S-ATA ADA-QLS-HUM	S-ATA w/confirmation ADA-QNS-HUM	S-ATA (Free/Total Ab) ADA-QNFT-HUM
Required Volume (µl)	20	20	40
Total Time (min)	140	140	95
Sample	Serum, plasma	Serum, plasma	Serum, plasma
Sample Number	96	96	96
Detection Limit (ng/ml)	+ / -	7,5	250
Spike Recovery (%)	-	Between 85 - 115	Between 85 - 115
Shelf Life (year)	1	1	1
Assay Type	Qualitative	Quantitative	Semi Quantitative
Species Reactivity	Human	Human	Human
Storage Conditions	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.
Shipping Conditions	At room temperature	At room temperature	At room temperature

ADALIMUMAB，阿达木单抗 SHIKARI®

Q-ADA • S-ATA • S-ATA w/confirmation • S-ATA (Free/Total Ab)

ADALIMUMAB (Humira®) ELISA

Adalimumab through concentration (TC) measurement



Matriks 中国区总代理，艾美捷科技，400-6800-868

AFLIBERCEPT, 阿柏西普 SHIKARI®

Q-AF • Q-AF HIGH SENSITIVE • S-ATAF • Q-ATAF w/confirmation

AFLIBERCEPT (Eylea®) ELISA

Aflibercept is a vascular endothelial growth factor (VEGF) inhibitor used to treat Neovascular (Wet) Age-Related Macular Degeneration (AMD), various types of macular edema and diabetic retinopathy. Aflibercept is a recombinant protein composed of the binding domains of two human vascular endothelial growth factor (VEGF) receptors fused with the Fc region of human immunoglobulin gamma 1 (IgG1). Ablibercept is a recombinant fusion protein that acts as a decoy receptor for the ligands, vascular endothelial growth factor-A (VEGF-A) and placental growth factor (PlGF). It prevents these ligands to binding to endothelial receptors, VEGFR-1 and VEGFR-2, to suppress neovascularization and decrease vascular permeability. This ultimately will slow vision loss or the progression of metastatic colorectal cancer. Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary.

SHIKARI® Q-AF: Enzyme immunoassay for the quantitative determination of Aflibercept (Eylea®) in serum and plasma. This kit has been especially developed for the quantitative determination of Aflibercept in serum and plasma samples between the Cmin and Cmax range of concentrations.

Shikari® (Q-AF) Aflibercept ELISA



Catalog Number/Code	**Q-AF** AFL-FD-EYL
Required Volume (µl)	5
Total Time (min)	105
Sample	Serum, plasma
Sample Number	96
Detection Limit (ng/ml)	10
Spike Recovery (%)	Between 85 - 115
Shelf Life (year)	1
Assay Type	Quantitative
Species Reactivity	Human
Storage Conditions	Store at +4°C. Please refer to protocols.
Shipping Conditions	At room temperature

AFLIBERCEPT, 阿柏西普 SHIKARI®

Q-AF • Q-AF HIGH SENSITIVE • S-ATAF • S-ATAF w/confirmation

AFLIBERCEPT (Eylea®) ELISA

SHIKARI® Q-AF HIGH SENSITIVE: Enzyme immunoassay for the quantitative determination of Aflibercept (Eylea®) in serum and plasma. This kit has been especially developed for the quantitative determination of Aflibercept in serum and plasma samples between the Cmin and Cmax range of concentrations.

SHIKARI® S-ATAF: Enzyme immunoassay for the quantitative determination of antibodies to of Aflibercept (Eylea®) in serum and plasma with confirmation. This kit has been especially developed for the quantitative antibodies to Aflibercept in serum and plasma samples.

SHIKARI® S-ATAF w/confirmation: Enzyme immunoassay for the quantitative determination of antibodies to of Aflibercept (Eylea®) in serum and plasma with confirmation. This kit has been especially developed for the quantitative antibodies to Aflibercept in serum and plasma samples.

Shikari® (Q-AF HIGH SENSITIVE) Aflibercept ELISA



Shikari® (S-ATAF) Anti-Aflibercept ELISA w/confirmation



Catalog Number/Code	Q-AF HIGH SENS. AFL-FD-SENS-EYL	S-ATAF AFL-QLS-EYL	S-ATAF w/confirmation AFL-QNS-EYL
Required Volume (µl)	50	20	50
Total Time (min)	105	140	110
Sample	Serum, plasma	Serum, plasma	Serum, plasma
Sample Number	96	96	96
Detection Limit (ng/ml)	1	+ / -	1
Spike Recovery (%)	Between 85 - 115	-	Between 85 - 115
Shelf Life (year)	1	1	1
Assay Type	Quantitative	Qualitative	Quantitative
Species Reactivity	Human	Human	Human
Storage Conditions	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.
Shipping Conditions	At room temperature	At room temperature	At room temperature

ATEZOLIZUMAB, 阿替利珠单抗 SHIKARI®

Q-ATE • S-ATAT

ATEZOLIZUMAB (Tecentriq®) ELISA

Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers such as advanced or metastatic urothelial carcinoma. This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum based chemotherapy, or whose tumors do not respond to platinum based chemotherapy. Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary.

SHIKARI® Q-ATE: Enzyme immunoassay for the quantitative determination of Atezolizumab (Tecentriq®) in serum and plasma. This kit has been especially developed for the quantitative determination of Atezolizumab in serum and plasma samples between the Cmin and Cmax range of concentrations.

SHIKARI® S-ATAT: Enzyme immunoassay for the qualitative determination of specific antibodies to Atezolizumab (Tecentriq®) in serum and plasma. This kit has been especially developed for the qualitative determination of specific antibodies to Atezolizumab in serum and plasma samples.

Shikari® (Q-ATE) Atezolizumab ELISA



Catalog Number/Code	**Q-ATE** ATE-FD-TEC	**S-ATAT** ATE-QLS-TEC
Required Volume (µl)	10	20
Total Time (min)	70	140
Sample	Serum, plasma	Serum, plasma
Sample Number	96	96
Detection Limit (ng/ml)	5	+ / -
Spike Recovery (%)	Between 85 - 115	-
Shelf Life (year)	1	1
Assay Type	Quantitative	Qualitative
Species Reactivity	Human	Human
Storage Conditions	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.
Shipping Conditions	At room temperature	At room temperature

AVELUMAB, 阿维鲁单抗 SHIKARI®

Q-AVE • S-ATAV

AVELUMAB (Bavencio®) ELISA

Avelumab is a monoclonal antibody used to treat metastatic merkel cell carcinoma, metastatic urothelial carcinoma, or renal cell carcinoma. Avelumab binds PD-L1 through the FG loops 7 and blocks the interaction between PD-L1 and its receptors PD-1 and B7.1. This interaction releases the inhibitory effects of PD-L1 on the immune response resulting in the restoration of immune responses, including anti-tumor immune responses. Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary.

SHIKARI® Q-AVE: Enzyme immunoassay for the quantitative determination of free Avelumab (Bavencio®) in serum and plasma. This kit has been especially developed for the quantitative determination of avelumab in serum and plasma samples between the Cmin and Cmax range of concentrations.

SHIKARI® S-ATAV: Enzyme immunoassay for the qualitative determination of antibodies to Avelumab (Bavencio®) in serum and plasma. This kit has been especially developed for the qualitative determination of antibodies to Avelumab in serum and plasma.

Shikari® (Q-AVE) Avelumab ELISA



Catalog Number/Code	**Q-AVE** AVE-FD-BAV	**S-ATAV** AVE-QLS-BAV
Required Volume (µl)	10	20
Total Time (min)	70	140
Sample	Serum, plasma	Serum, plasma
Sample Number	96	96
Detection Limit (ng/ml)	30	+ / -
Spike Recovery (%)	Between 85 - 115	-
Shelf Life (year)	1	1
Assay Type	Quantitative	Qualitative
Species Reactivity	Human	Human
Storage Conditions	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.
Shipping Conditions	At room temperature	At room temperature

BEVACIZUMAB, 贝伐珠单抗 SHIKARI®

Q-BEVA • S-ATB • S-ATB w/confirmation

BEVACIZUMAB (Avastin®) ELISA

Bevacizumab is a monoclonal anti-vascular endothelial growth factor antibody used in combination with antineoplastic agents for the treatment of many types of cancer.

There is a great deal of evidence indicating that vascular endothelial growth factor (VEGF) is important for the survival and proliferation of cancer cells. It is a humanized monoclonal IgG antibody, and inhibits angiogenesis by binding and neutralizing VEGF-A. Bevacizumab is generally indicated for use in combination with different chemotherapy regimens which are specific to the type, severity, and stage of cancer. Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary.

SHIKARI® Q-BEVA: Enzyme immunoassay for the quantitative determination of free Bevacizumab (Avastin®) in serum and plasma. This kit has been especially developed for the quantitative determination of Bevacizumab in serum and plasma samples between the Cmin and Cmax range of concentrations.

Shikari® (Q-BEVA) Bevacizumab ELISA



Catalog Number/Code	**Q-BEVA** BEV-FD-AA
Required Volume (µl)	10
Total Time (min)	70
Sample	Serum, plasma
Sample Number	96
Detection Limit (ng/ml)	30
Spike Recovery (%)	Between 85 - 115
Shelf Life (year)	1
Assay Type	Quantitative
Species Reactivity	Human
Storage Conditions	Store at +4°C. Please refer to protocols.
Shipping Conditions	At room temperature

BEVACIZUMAB, 贝伐珠单抗 SHIKARI®

Q-BEVA • S-ATB • S-ATB w/confirmation

BEVACIZUMAB (Avastin®) ELISA

SHIKARI® S-ATB: Enzyme immunoassay for the qualitative determination of specific antibodies to Bevacizumab (Avastin®) in serum and plasma. This kit has been especially developed for the qualitative determination of specific antibodies to Bevacizumab in serum and plasma samples.

SHIKARI® S-ATB w/confirmation: Enzyme immunoassay for the quantitative determination of antibodies to Bevacizumab (Avastin®) in serum and plasma with confirmation. This kit has been especially developed for the quantitative antibodies to Bevacizumab in serum and plasma samples.

Shikari® (S-ATB) Anti-Bevacizumab ELISA w/confirmation



Catalog Number/Code	**S-ATB** BEV-QLS-AA	**S-ATB w/confirmation** BEV-QNS-AA
Required Volume (µl)	20	20
Total Time (min)	140	140
Sample	Serum, plasma	Serum, plasma
Sample Number	96	96
Detection Limit (ng/ml)	+ / -	7,5
Spike Recovery (%)	-	Between 85 - 115
Shelf Life (year)	1	1
Assay Type	Qualitative	Quantitative
Species Reactivity	Human	Human
Storage Conditions	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.
Shipping Conditions	At room temperature	At room temperature

CANAKINUMAB, 卡那单抗 SHIKARI®

Q-CAN • S-ATCAN • S-ATCAN w/confirmation

CANAKINUMAB (Ilaris®) ELISA

Canakinumab is a human interleukin-1β blocker and neutralizes its inflammatory activity by blocking its interaction with IL-1 receptors, but it does not bind IL-1alpha or IL-1 receptor antagonist (IL-1ra). Canakinumab is used to treat Periodic Fever Syndromes such as Cryopyrin-Associated Periodic Syndromes (CAPS) and Familial Mediterranean Fever (FMF), and also to treat active Systemic Juvenile Idiopathic Arthritis (SJIA). Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary.

SHIKARI® Q-CAN: Enzyme immunoassay for the quantitative determination of Canakinumab (Ilaris®) in serum and plasma. This kit has been especially developed for the quantitative determination of Canakinumab in serum and plasma samples between the Cmin and Cmax range of concentrations.

SHIKARI® S-ATCAN: Enzyme immunoassay for the qualitative determination of specific antibodies to Canakinumab (Ilaris®) in serum and plasma. This kit has been especially developed for the qualitative determination of specific antibodies to Canakinumab in serum and plasma samples.

SHIKARI® S-ATCAN w/confirmation: Enzyme immunoassay for the quantitative determination of specific antibodies to Canakinumab (Ilaris®) in serum and plasma. This kit has been especially developed for the qualitative determination of specific antibodies to Canakinumab in serum and plasma samples.

Shikari® (Q-CAN) Canakinumab ELISA



Shikari® (S-ATCAN) Anti-Canakinumab ELISA w/confirmation



Catalog Number/Code	Q-CAN CAN-FD-ILA	S-ATCAN CAN-QLS-ILA	S-ATCAN w/confirmation CAN-QNS-ILA
Required Volume (µl)	10	20	20
Total Time (min)	70	140	140
Sample	Serum, plasma	Serum, plasma	Serum, plasma
Sample Number	96	96	96
Detection Limit (ng/ml)	1	+ / -	31,25
Spike Recovery (%)	Between 85 - 115	-	Between 85 - 115
Shelf Life (year)	1	1	1
Assay Type	Quantitative	Qualitative	Quantitative
Species Reactivity	Human	Human	Human
Storage Conditions	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.
Shipping Conditions	At room temperature	At room temperature	At room temperature

CERTOLIZUMAB, 塞妥珠单抗 SHIKARI®

Q-CERT • S-ATCER w/confirmation

CERTOLIZUMAB (Cimzia®) ELISA

Certolizumab pegol is a tumor necrosis factor (TNF) blocker used to treat a variety of autoimmune and autoinflammatory conditions like Crohn's disease, rheumatoid arthritis, active psoriatic arthritis, ankylosing spondylitis, axial spondyloarthritis, and plaque psoriasis. Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent complement fixation and antibody-mediated cytotoxicity as well as to markedly increase its half-life.

SHIKARI® Q-CERT: Enzyme immunoassay for the quantitative determination of Certolizumab (Cimzia®) in serum and plasma. This kit has been especially developed for the quantitative determination of certolizumab in serum and plasma samples between the Cmin and Cmax range of concentrations.

SHIKARI® S-ATCER w/confirmation: Enzyme immunoassay for the quantitative determination of antibodies to Certolizumab (Cimzia®) in serum and plasma with confirmation. This kit has been especially developed for the quantitative antibodies to Certolizumab in serum and plasma samples.

Shikari® (Q-CERT) Certolizumab ELISA



Shikari® (S-ATCER) Anti-Certolizumab ELISA w/confirmation



Catalog Number/Code	**Q-CERT** CER-FD-CIM	**S-ATCER w/confirmation** CER-QNS-CIM
Required Volume (µl)	10	5
Total Time (min)	70	140
Sample	Serum, plasma	Serum, plasma
Sample Number	96	96
Detection Limit (ng/ml)	20	5
Spike Recovery (%)	Between 85 - 115	Between 85 - 115
Shelf Life (year)	1	1
Assay Type	Quantitative	Quantitative
Species Reactivity	Human	Human
Storage Conditions	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.
Shipping Conditions	At room temperature	At room temperature

CETUXIMAB，西妥昔单抗
SHIKARI®

Q-CET • S-ATC • S-ATC w/confirmation

CETUXIMAB (Erbitux®) ELISA

Cetuximab is an endothelial growth factor receptor binding fragment used to treat colorectal cancer as well as squamous cell carcinoma of the head and neck. Cetuximab is a recombinant chimeric human/mouse IgG1 monoclonal antibody that competitively binds to epidermal growth factor receptor (EGFR) and competitively inhibits the binding of epidermal growth factor (EGF). EGFR is a member of the ErbB family of receptor tyrosine kinases found in both normal and tumour cells; it is responsible for regulating epithelial tissue development and homeostasis. Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary.

SHIKARI® Q-CET: Enzyme immunoassay for the quantitative determination of Cetuximab (Erbitux®) in serum and plasma. This kit has been especially developed for the quantitative determination of Cetuximab in serum and plasma samples between the Cmin and Cmax range of concentrations.

SHIKARI® S-ATC: Enzyme immunoassay for the qualitative determination of specific antibodies to Cetuximab (Erbitux®) in human serum and plasma. This kit has been especially developed for the qualitative determination of Cetuximab in serum and plasma samples.

SHIKARI® S-ATC w/confirmation: Enzyme immunoassay for the quantitative determination of antibodies to Cetuximab (Erbitux®) in serum and plasma with confirmation. This kit has been especially developed for the quantitative antibodies to cetuximab in serum and plasma samples.

Shikari® (Q-CET) Cetuximab ELISA



Shikari® (S-ATC) Anti-Cetuximab ELISA w/confirmation



Catalog Number/Code	**Q-CET** CET-FD-ERB	**S-ATC** CET-QLS-ERB	**S-ATC w/confirmation** CET-QNS-ERB
Required Volume (µl)	10	20	20
Total Time (min)	70	140	140
Sample	Serum, plasma	Serum, plasma	Serum, plasma
Sample Number	96	96	96
Detection Limit (ng/ml)	30	+ / -	30
Spike Recovery (%)	Between 85 - 115	-	Between 85 - 115
Shelf Life (year)	1	1	1
Assay Type	Quantitative	Qualitative	Quantitative
Species Reactivity	Human	Human	Human
Storage Conditions	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.
Shipping Conditions	At room temperature	At room temperature	At room temperature

DARATUMUMAB，达雷木单抗 SHIKARI®

Q-DAR • S-ATDAR

DARATUMUMAB (Darzalex®) ELISA

Daratumumab is a CD38-directed cytolytic monoclonal antibody that targets CD38+ multiple myeloma cells. Daratumumab is used alone or as an adjunct drug in the treatment of multiple myeloma and light chain amyloidosis. Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary.

SHIKARI® Q-DAR: Enzyme immunoassay for the quantitative determination of Daratumumab (Darzalex®) in serum and plasma. This kit has been especially developed for the quantitative determination of Daratumumab in serum and plasma samples between the Cmin and Cmax range of concentrations.

SHIKARI® S-ATDAR: Enzyme immunoassay for the qualitative determination of specific antibodies to Daratumumab (Darzalex®) in serum and plasma. This kit has been especially developed for the qualitative determination of specific antibodies to Daratumumab in serum and plasma samples.

Shikari® (Q-DAR) Daratumumab ELISA



Catalog Number/Code	**Q-DAR** DAR-FD-DAR	**S-ATDAR** DAR-QLS-DAR
Required Volume (µl)	5	20
Total Time (min)	100	140
Sample	Serum, plasma	Serum, plasma
Sample Number	96	96
Detection Limit (ng/ml)	10	+ / -
Spike Recovery (%)	Between 85 - 115	-
Shelf Life (year)	1	1
Assay Type	Quantitative	Qualitative
Species Reactivity	Human	Human
Storage Conditions	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.
Shipping Conditions	At room temperature	At room temperature



DENOSUMAB, 地舒单抗 SHIKARI®

Q-DEN • S-ATD • S-ATD w/confirmation

DENOSUMAB (Prolia®) ELISA

Denosumab is a RANK ligand (RANKL) inhibitor used for the management of osteoporosis in patients at high risk for bone fractures. Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption markers in patients with a variety of metastatic tumors and is being investigated in multiple clinical trials for the prevention and treatment of bone metastases. Denosumab is designed to target RANKL (RANK ligand), a protein that acts as the primary signal to promote bone removal/resorption. In many bone loss conditions, RANKL overwhelms the body's natural defense against bone destruction. Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary.

SHIKARI® Q-DEN: Enzyme immunoassay for the quantitative determination of denosumab (Prolia®) in serum and plasma. This kit has been especially developed for the quantitative determination of denosumabin serum and plasma samples between the Cmin and Cmax range of concentrations.

SHIKARI® S-ATD: Enzyme immunoassay for the qualitative determination of specific antibodies to denosumab (Prolia®) in human serum and plasma. This kit has been especially developed for the qualitative determination of denosumab in serum and plasma samples.

SHIKARI® S-ATD w/confirmation: Enzyme immunoassay for the quantitative determination of antibodies to denosumab (Prolia®) in serum and plasma with confirmation. This kit has been especially developed for the quantitative antibodies to denosumab in serum and plasma samples.

Shikari® (Q-DEN) Denosumab ELISA



Shikari® (S-ATD) Anti-Denosumab ELISA w/confirmation



Catalog Number/Code	**Q-DEN** DEN-FD-PRO	**S-ATD** DEN-QLS-PRO	**S-ATD w/confirmation** DEN-QNS-PRO
Required Volume (µl)	10	20	5
Total Time (min)	70	140	140
Sample	Serum, plasma	Serum, plasma	Serum, plasma
Sample Number	96	96	96
Detection Limit (ng/ml)	10	+ / -	18,75
Spike Recovery (%)	Between 85 - 115	-	Between 85 - 115
Shelf Life (year)	1	1	1
Assay Type	Quantitative	Qualitative	Quantitative
Species Reactivity	Human	Human	Human
Storage Conditions	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.
Shipping Conditions	At room temperature	At room temperature	At room temperature

DURVALUMAB, 度伐利尤单抗 SHIKARI®

Q-DUR • S-ATDUR

DURVALUMAB (Imfinzi®) ELISA

Durvalumab is an antineoplastic monoclonal antibody used to treat urothelial carcinoma and locally advanced, unresectable non-small cell lung cancer. Durvalumab blocks programmed death-ligand 1 (PD-L1) to promote normal immune responses that attack tumour cells. . Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary.

SHIKARI® Q-DUR: Enzyme immunoassay for the quantitative determination of Durvalumab (Imfinzi®) in serum and plasma. This kit has been especially developed for the quantitative determination of Durvalumab in serum and plasma samples between the Cmin and Cmax range of concentrations.

SHIKARI® S-ATDUR: Enzyme immunoassay for the qualitative determination of specific antibodies to Durvalumab (Imfinzi®) in serum and plasma. This kit has been especially developed for the qualitative determination of specific antibodies to Durvalumab in serum and plasma samples.

Shikari® (Q-DUR) Durvalumab ELISA



Catalog Number/Code	**Q-DUR** DUR-FD-IMF	**S-ATDUR** DUR-QLS-IMF
Required Volume (µl)	10	20
Total Time (min)	70	140
Sample	Serum, plasma	Serum, plasma
Sample Number	96	96
Detection Limit (ng/ml)	6	+ / -
Spike Recovery (%)	Between 85 - 115	-
Shelf Life (year)	1	1
Assay Type	Quantitative	Qualitative
Species Reactivity	Human	Human
Storage Conditions	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.
Shipping Conditions	At room temperature	At room temperature

ECULIZUMAB, 依库珠单抗 SHIKARI®

Q-ECU • S-ATEC • S-ATEC

ECULIZUMAB (Soliris®) ELISA

Eculizumab is a recombinant humanized monoclonal antibody that targets complement protein C5, preventing cleavage to C5a and C5b, and the formation of the terminal complement complex C5b-9. Binding to this protein prevents the activation of a complement terminal complex, which is used to treat a number of autoimmune conditions. By the inhibition of this complex, eculizumab is indicated to treat paroxysmal nocturnal hemoglobinuria (PNH) to reduce the risk of complement mediated intravascular hemolysis, to prevent complement mediated microangiopathy in atypical hemolytic uremic syndrome and immune mediated inflammation and damage of the central nervous system in neuromyelitis optica spectrum disorder (NMOSD).

SHIKARI® Q-ECU: Enzyme immunoassay for the quantitative determination of specific Eculizumab (Soliris®) in serum and plasma. This kit has been especially developed for the quantitative analysis of free eculizumab in serum and plasma samples between the Cmin and Cmax range of concentrations.

SHIKARI® S-ATEC: Enzyme immunoassay for the qualitative determination of specific antibodies to Eculizumab (Soliris®) in serum and plasma. This kit has been especially developed for the qualitative analysis of antibodies to Eculizumab in serum and plasma samples.

SHIKARI® S-ATEC: Enzyme immunoassay for the quantitative determination of specific antibodies to Eculizumab (Soliris®) in serum and plasma. This kit has been especially developed for the quantitative analysis of antibodies to Eculizumab in serum and plasma samples.

Shikari® (Q-ECU) Eculizumab ELISA



Shikari® (S-ATEC) Anti-Eculizumab ELISA w/confirmation



Catalog Number/Code	**Q-ECU** ECU-FD-SOL	**S-ATEC** ECU-QLS-SOL	**S-ATEC w/confirmation** ECU-QNS-SOL
Required Volume (µl)	10	20	5
Total Time (min)	100	140	140
Sample	Serum, plasma	Serum, plasma	Serum, plasma
Sample Number	96	96	96
Detection Limit (ng/ml)	4,68	+ / -	6,25
Spike Recovery (%)	Between 85 - 115	-	Between 85 - 115
Shelf Life (year)	1	1	1
Assay Type	Quantitative	Qualitative	Quantitative
Species Reactivity	Human	Human	Human
Storage Conditions	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.
Shipping Conditions	At room temperature	At room temperature	At room temperature

ETANERCEPT, 依那西普 SHIKARI®

Q-ETA S-ATE

ETANERCEPT (Enbrel®) ELISA

Etanercept is a protein therapy based on the binding fragment of the tumour necrosis factor alpha receptor used to treat severe rheumatoid arthritis and moderate to severe plaque psoriasis. Etanercept binds specifically to tumor necrosis factor (TNF) and thereby modulates biological processes that are induced or regulated by TNF.7,5 Such processes or molecules affected include the level of adhesion molecules expressed, as well as serum levels of cytokines and matrix metalloproteinases.

Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary.

SHIKARI® Q-ETA: Enzyme immunoassay for the quantitative determination of free Etanercept (Enbrel®) in serum and plasma. This kit has been especially developed for the quantitative determination of etanercept in serum and plasma samples between the Cmin and Cmax range of concentrations.

SHIKARI® S-ATE: Enzyme immunoassay for the quantitative determination of free Etanercept (Enbrel®) in serum and plasma. This kit has been especially developed for the qualitative antibodies to Etanercept in serum and plasma samples.

Shikari® (Q-ETA) Etanercept ELISA



Catalog Number/Code	**Q-ETA** ETA-FD-ENB	**S-ATE** ETA-QLS-ENB
Required Volume (µl)	10	20
Total Time (min)	70	140
Sample	Serum, plasma	Serum, plasma
Sample Number	96	96
Detection Limit (ng/ml)	100	+ / -
Spike Recovery (%)	Between 85 - 115	-
Shelf Life (year)	1	1
Assay Type	Quantitative	Qualitative
Species Reactivity	Human	Human
Storage Conditions	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.
Shipping Conditions	At room temperature	At room temperature

EVOLOCUMAB，依洛尤单抗 SHIKARI®

Q-EVO • S-ATEVO

EVOLOCUMAB (Repatha®) ELISA

Evolocumab is a PCSK9 (proprotein convertase subtilisin kexin type 9) inhibitor antibody used as an adjunct to LDL cholesterol reducing therapies, aiding in the prevention of cardiovascular events and cardiovascular revascularization procedures. Evolocumab is a human IgG2 monoclonal antibody that targets the proprotein convertase subtilisin/kexin type 9 (PCSK9). Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary.

SHIKARI® Q-EVO: Enzyme immunoassay for the quantitative determination of Evolocumab (Repatha®) in serum and plasma. This kit has been especially developed for the quantitative determination of evolocumab in serum and plasma samples between the Cmin and Cmax range of concentrations.

SHIKARI® S-ATEVO: Enzyme immunoassay for the qualitative determination of specific antibodies to Evolocumab (Repatha®) in serum and plasma. This kit has been especially developed for the qualitative determination of specific antibodies to Evolocumab in serum and plasma samples.

Shikari® (Q-EVO) Evolocumab ELISA



Catalog Number/Code	**Q-EVO** EVO-FD-REP	**S-ATEVO** EVO-QLS-REP
Required Volume (µl)	10	20
Total Time (min)	140	140
Sample	Serum, plasma	Serum, plasma
Sample Number	96	96
Detection Limit (ng/ml)	6	+ / -
Spike Recovery (%)	Between 85 - 115	-
Shelf Life (year)	1	1
Assay Type	Quantitative	Qualitative
Species Reactivity	Human	Human
Storage Conditions	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.
Shipping Conditions	At room temperature	At room temperature

FILGRASTIM, 非格司亭 SHIKARI®

Q-AFA w/confirmation

FILGRASTIM (Fraven®) ELISA

Filgrastim (Fraven®) was associated to the development of anti-Filgrastim antibodies, even some were reported to be neutralizing, in various percentages of patients during therapy with the drug Fraven®. This might lead to severe complications. This kit can be efficiently used for monitoring anti-Filgrastim antibodies during therapy and offers theclinician a tool for decision on possible preventive measures such as possible addition of immunosuppressive drug to reduce anti-Filgrastim antibodies.

SHIKARI® Q-AFA: Enzyme immunoassay for the quantitative determination of antibodies to o Filgrastim (Fraven®) in serum and plasma with confirmation. This kit has been especially developed for the quantitative antibodies to Filgrastim in serum and plasma samples.

Shikari® (Q-AFA) Anti-Filgrastim ELISA w/confirmation



Catalog Number/Code	Q-AFA w/confirmation FIL-QNS-FRA
Required Volume (µl)	10
Total Time (min)	140
Sample	Serum, plasma
Sample Number	96
Detection Limit (ng/ml)	2
Spike Recovery (%)	Between 85 - 115
Shelf Life (year)	1
Assay Type	Quantitative
Species Reactivity	Human
Storage Conditions	Store at +4°C. Please refer to protocols.
Shipping Conditions	At room temperature

GOLIMUMAB，戈利木单抗 SHIKARI®

Q-GOL • S-ATG • S-ATG w/confirmation

GOLIMUMAB (Simponi®) ELISA

Golimumab is a TNFα inhibitor used in the symptomatic treatment of various active inflammatory disorders, such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis. Golimumab is a human IgG1κ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation.

SHIKARI® Q-GOL: Enzyme immunoassay for the quantitative determination of Golimumab (Simponi®) in serum and plasma. This kit has been especially developed for the quantitative determination of golimumab in serum and plasma samples between the Cmin and Cmax range of concentrations.

SHIKARI® S-ATG: Enzyme immunoassay for the quantitative determination of antibodies to Golimumab (Simponi®) in serum and plasma. This kit has been especially developed for the qualitative determination of antibodies to Golimumab in serum and plasma samples.

SHIKARI® S-ATG w/confirmation: Enzyme immunoassay for the quantitative determination of antibodies to o Golimumab (Simponi®) in serum and plasma with confirmation. This kit has been especially developed for the quantitative determination of antibodies to Golimumab in serum and plasma samples.

Shikari® (Q-GOL) Golimumab ELISA



Shikari® (S-ATG) Anti-Golimumab ELISA w/confirmation



Catalog Number/Code	Q-GOL GOL-FD-SIM	S-ATG GOL-QLS-SIM	S-ATG w/confirmation GOL-QNS-SIM
Required Volume (µl)	20	20	20
Total Time (min)	70	140	140
Sample	Serum, plasma	Serum, plasma	Serum, plasma
Sample Number	96	96	96
Detection Limit (ng/ml)	10	+ / -	18,75
Spike Recovery (%)	Between 85 - 115	-	Between 85 - 115
Shelf Life (year)	1	1	1
Assay Type	Quantitative	Qualitative	Quantitative
Species Reactivity	Human	Human	Human
Storage Conditions	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.
Shipping Conditions	At room temperature	At room temperature	At room temperature

INFLIXIMAB，英夫利昔单抗
SHIKARI®

Q-INFLIXI • QS-INFLIXI • Q-ATI • Q-ATI w/confirmation • Q-ATI (Free/Total Ab)

INFILIXIMAB (Remicade®) ELISA

Infliximab is a monoclonal anti-tumor necrosis factor alpha antibody used in the treatment of a wide variety of inflammatory conditions such as rheumatoid arthritis, Crohn's disease and ankylosing spondylitis. Infliximab binds with high affinity to soluble and transmembrane forms of TNF-α to disrupt the proinflammatory cascade signaling. Binding of antibodies to TNF-a prevents TNF-a from interacting with its receptors and helps the patient recover. Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary.

SHIKARI® Q-INFLIXI: Enzyme immunoassay for the quantitative determination of Infliximab (Remicade®) in serum and plasma. This kit has been especially developed for the quantitative Infliximab in serum and plasma samples between the Cmin and Cmax range of concentrations.

SHIKARI® QS-INFLIXI: Infliximab ELISA has been especially developed for the specific and quantitative analysis of free infliximab in serum and plasma samples.

Shikari® (Q-INFLIXI) Infliximab ELISA



Shikari® (QS-INFLIXI) Infliximab ELISA



Catalog Number/Code	**Q-INFLIXI** INF-FD-REMI	**QS-INFLIXI** INF-SPEC-INF
Required Volume (µl)	10	10
Total Time (min)	70	70
Sample	Serum, plasma	Serum, plasma
Sample Number	96	96
Detection Limit (ng/ml)	10	0,003
Spike Recovery (%)	Between 85 - 115	Between 85 - 115
Shelf Life (year)	1	1
Assay Type	Quantitative	Quantitative
Species Reactivity	Human	Human
Storage Conditions	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.
Shipping Conditions	At room temperature	At room temperature

INFLIXIMAB，英夫利昔单抗 SHIKARI®

Q-INFLIXI • QS-INFLIXI • Q-ATI • Q-ATI w/confirmation • Q-ATI (Free/Total Ab)

INFILIXIMAB (Remicade®) ELISA

Demonstration of anti-infliximab antibodies during treatment with infliximab (Remicade®) has a major concern and monitoring for the presence and/or quantitation of specific antibodies during clinical trials is an important issue for follow up of the treatment regimens. With the Matriks Biotek® SHIKARI® Q-ATI Total/Free ADA ELISA Kit infliximabspecific antibodies that are free and bound infliximab in serum and cannot be detected by free antibody detection kits can be determined in patients receiving Remicade®.

SHIKARI® Q-ATI: Enzyme immunoassay for the qualitative determination of antibodies to Infliximab (Remicade®) in serum and plasma. This kit has been especially developed for the qualitative antibodies to Infliximab in serum and plasma samples.

SHIKARI® Q-ATI w/confirmation: Enzyme immunoassay for the quantitative determination of antibodies to Infliximab (Remicade®) in serum and plasma with confirmation. This kit has been especially developed for the quantitative antibodies to Infliximab in serum and plasma samples.

SHIKARI® Q-ATI (Free/Total Ab): Enzyme immunoassay for the semi-quantitative determination (screening) of total and free antibodies to infliximab in serum and plasma.

Shikari® (Q-ATI) Anti-Infliximab ELISA w/confirmation



Catalog Number/Code	**Q-ATI** INF-QLS-REMI	**Q-ATI w/confirmation** INF-QNS-REMI	**Q-ATI (Free/Total Ab)** INF-QNFT-REMI
Required Volume (µl)	20	20	40
Total Time (min)	140	140	95
Sample	Serum, plasma	Serum, plasma	Serum, plasma
Sample Number	96	96	96
Detection Limit (ng/ml)	+ / -	3,125	156
Spike Recovery (%)	-	Between 85 - 115	-
Shelf Life (year)	1	1	1
Assay Type	Qualitative	Quantitative	Semi Qualitative
Species Reactivity	Human	Human	Human
Storage Conditions	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.
Shipping Conditions	At room temperature	At room temperature	At room temperature

INFLIXIMAB，英夫利昔单抗
SHIKARI®

Q-INFLIXI • QS-INFLIXI • Q-ATI • Q-ATI w/confirmation • Q-ATI (Free/Total Ab)

INFILIXIMAB (Remicade®) ELISA

Infliximab through concentration (TC) measurement



Matriks 中国区总代理，艾美捷科技，400-6800-868

INFLIXIMAB BIOSIMILAR, 英夫利昔类似物 SHIKARI®

Q-REMS • S-AIR • S-AIR w/confirmation • S-AIR (Free/Total Ab)

INFLIXIMAB BIOSIMILAR (Remsima®) ELISA

Infliximab is a monoclonal anti-tumor necrosis factor alpha antibody used in the treatment of a wide variety of inflammatory conditions such as rheumatoid arthritis, Crohn's disease and ankylosing spondylitis. Infliximab binds with high affinity to soluble and transmembrane forms of TNF-α to disrupt the proinflammatory cascade signaling. Binding of antibodies to TNF-a prevents TNF-a from interacting with its receptors and helps the patient recover. Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary.

Remsima®, the world first biosimilar mAb (approved in 2013 by EMA). The Agencys Committee for Medicinal Products for Human Use (CHMP) decided that, in accordance with EU requirements, Remsima® has been shown to have a comparable quality, safety and efficacy profile to Remicade®.

SHIKARI® Q-REMS: Enzyme immunoassay for the quantitative determination of free Infliximab-biosimilar (Remsima®) in serum and plasma. This kit has been especially developed for the quantitative determination of infliximabbiosimilar (Remsima®) in serum and plasma samples between the Cmin and Cmax range of concentrations.

SHIKARI® S-AIR: Enzyme immunoassay for the qualitative determination of antibodies to infliximab-biosimilar (Remsima®) in serum and plasma. This kit has been especially developed for the qualitative antibodies to infliximabbiosimilar (Remsima®) in serum and plasma samples.

Shikari® (Q-REMS) Infliximab Biosimilar ELISA



Catalog Number/Code	**Q-REMS** INF-FD-REMS	**S-AIR** INF-QLS-REMS
Required Volume (µl)	10	20
Total Time (min)	70	140
Sample	Serum, plasma	Serum, plasma
Sample Number	96	96
Detection Limit (ng/ml)	10	+ / -
Spike Recovery (%)	Between 85 - 115	-
Shelf Life (year)	1	1
Assay Type	Quantitative	Qualitative
Species Reactivity	Human	Human
Storage Conditions	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.
Shipping Conditions	At room temperature	At room temperature

INFLIXIMAB BIOSIMILAR，英夫利昔类似物 SHIKARI®

Q-REMS • S-AIR • S-AIR w/confirmation • S-AIR (Free/Total Ab)

INFLIXIMAB BIOSIMILAR (Remsima®) ELISA

SHIKARI® S-AIR w/confirmation: Enzyme immunoassay for the quantitative determination of antibodies to Infliximabbiosimilar (Remsima®) in serum and plasma with confirmation. SHIKARI® Quantitative Antibodies to Infliximab Biosimilar ELISA has been especially developed for the quantitative analysis of antibodies to infliximab biosimilar in serum and plasma samples. This kit is optimized with Remsima®.

SHIKARI® S-AIR (Free/Total Ab): Enzyme immunoassay for the semi-quantitative determination (screening) of total antibodies to infliximab biosimilar (Remsima®) in serum and plasma.

Demonstration of anti-infliximab antibodies during treatment with infliximab- biosimilar (Remsima®) has a major concern and monitoring for the presence and/or quantitation of specific antibodies during clinical trials is an important issue for follow up of the treatment regimens. With the Matriks Biotek® SHIKARI® S-AIRv3 ELISA Kit infiliximab specific antibodies that are bound to infiliximab in serum and cannot be detected by free antibody detection kits can be determined in patients receiving Remsima®.

Shikari® (S-AIR) Anti-Infliximab biosimilar ELISA w/confirmation



Catalog Number/Code	S-AIR w/confirmation INF-QNS-REMS	S-AIR (Free/Total Ab) INF-QNFT-REMS
Required Volume (µl)	20	40
Total Time (min)	140	95
Sample	Serum, plasma	Serum, plasma
Sample Number	96	96
Detection Limit (ng/ml)	6,25	156
Spike Recovery (%)	Between 85 - 115	-
Shelf Life (year)	1	1
Assay Type	Quantitative	Semi Quantitative
Species Reactivity	Human	Human
Storage Conditions	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.
Shipping Conditions	At room temperature	At room temperature

IPILIMUMAB，伊匹单抗 SHIKARI®

Q-IPI • S-ATI • S-ATI w/confirmation

IPILIMUMAB (Yervoy®) ELISA

Ipilimumab is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody used to treat metastatic or unresectable melanoma. Ipilimumab binds to CTLA-4 on the cell surface, effectively blocking the interaction between CTLA-4 and B7.1/B7.2. This leads to interruption of the negative signal mediated by CTLA-4, the resumption of signal 2, and a relative restoration of T-cell activation. Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary.

SHIKARI® Q-IPI: Enzyme immunoassay for the quantitative determination of specific Ipilimumab (Yervoy®) in human serum and plasma. This kit has been especially developed for the quantitative determination of ipilimumab in serum and plasma samples between the Cmin and Cmax range of concentrations.

SHIKARI® S-ATI: Enzyme immunoassay for the qualitative determination of specific antibodies to Ipilimumab (Yervoy®) in human serum and plasma. This kit has been especially developed for the qualitative determination of antibodies to ipilimumab in serum and plasma.

SHIKARI® S-ATI w/confirmation: Enzyme immunoassay for the quantitative determination of specific antibodies to Ipilimumab (Yervoy®) in human serum and plasma. This kit has been especially developed for the quantitative determination of antibodies to ipilimumab in serum and plasma.

Shikari® (Q-IPI) Ipilimumab ELISA



Shikari® (S-ATI) Anti-Ipilimumab ELISA w/confirmation



Catalog Number/Code	**Q-IPI** IPI-FD-YER	**S-ATI** IPI-QLS-YER	**S-ATI w/confirmation** IPI-QNS-YER
Required Volume (µl)	10	20	20
Total Time (min)	70	140	140
Sample	Serum, plasma	Serum, plasma	Serum, plasma
Sample Number	96	96	96
Detection Limit (ng/ml)	3	+ / -	6,25
Spike Recovery (%)	Between 85 - 115	-	Between 85 - 115
Shelf Life (year)	1	1	1
Assay Type	Quantitative	Qualitative	Quantitative
Species Reactivity	Human	Human	Human
Storage Conditions	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.
Shipping Conditions	At room temperature	At room temperature	At room temperature

IXEKIZUMAB，依奇珠单抗 SHIKARI®

Q-IXE • S-ATIXE

IXEKIZUMAB (Taltz®) ELISA

IXEKIZUMABis a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody (mAb) against interleukin-17A (IL-17A) and prevents it from interacting with the IL-17A receptor. As IL-17A is a pro-inflammatory cytokine involved in inflammation and immune responses, blocking its effect is beneficial for use in inflammatory conditions. In particular, IL-17A has been found to be implicated in a variety of autoimmune diseases including Rheumatoid Arthritis and plaque psoriasis. Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary.

SHIKARI® Q-IXE: Enzyme immunoassay for the quantitative determination of Ixekizumab (Taltz®) in serum and plasma. This kit has been especially developed for the quantitative determination of Ixekizumab in serum and plasma samples between the Cmin and Cmax range of concentrations.

SHIKARI® S-ATIXE: Enzyme immunoassay for the qualitative determination of specific antibodies to Ixekizumab (Taltz®) in human serum and plasma. This kit has been especially developed for the qualitative determination of antibodies to Ixekizumab in serum and plasma samples.

Shikari® (Q-IXE) Ixekizumab ELISA



Catalog Number/Code	**Q-IXE** IXE-FD-TAL	**S-ATIXE** IXE-QLS-TAL
Required Volume (µl)	5	20
Total Time (min)	105	140
Sample	Serum, plasma	Serum, plasma
Sample Number	96	96
Detection Limit (ng/ml)	3	+ / -
Spike Recovery (%)	Between 85 - 115	-
Shelf Life (year)	1	1
Assay Type	Quantitative	Qualitative
Species Reactivity	Human	Human
Storage Conditions	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.
Shipping Conditions	At room temperature	At room temperature

NATALIZUMAB，那他珠单抗
SHIKARI®

Q-NAT • S-ATNAT • S-ATNAT w/confirmation

NATALIZUMAB (Tysabri®) ELISA

Natalizumab is a monoclonal anti-integrin antibody which binds to the alpha 4 subunit of integrins to prevent migration of immune cells, and is used to treat Crohn's disease or multiple sclerosis. Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary.

SHIKARI® Q-NAT: Enzyme immunoassay for the quantitative determination of specific Natalizumab (Tysabri®) in human serum and plasma. This kit has been especially developed for the quantitative determination of natalizumab in serum and plasma samples between the Cmin and Cmax range of concentrations.

SHIKARI® S-ATNAT: Enzyme immunoassay for the qualitative determination of specific antibodies to Natalizumab (Tysabri®) in human serum and plasma. This kit has been especially developed for the qualitative determination of natalizumab in serum and plasma samples.

SHIKARI® S-ATNAT w/confirmation: Enzyme immunoassay for the quantitative determination (screening) of antibodies to Natalizumab (Tysabri®) in serum and plasma with confirmation. This kit has been especially developed for the quantitative determination of antibodies to natalizumab in serum and plasma samples.

Shikari® (Q-NAT) Natalizumab ELISA



Shikari® (S-ATNAT) Anti-Natalizumab ELISA w/confirmation



Catalog Number/Code	**Q-NAT** NAT-FD-TYS	**S-ATNAT** NAT-QLS-TYS	**S-ATNAT w/confirmation** NAT-QNS-TYS
Required Volume (µl)	10	20	5
Total Time (min)	70	140	140
Sample	Serum, plasma	Serum, plasma	Serum, plasma
Sample Number	96	96	96
Detection Limit (ng/ml)	10	+ / -	1,87
Spike Recovery (%)	Between 85 - 115	-	Between 85 - 115
Shelf Life (year)	1	1	1
Assay Type	Quantitative	Qualitative	Quantitative
Species Reactivity	Human	Human	Human
Storage Conditions	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.
Shipping Conditions	At room temperature	At room temperature	At room temperature

NIVOLUMAB, 纳武单抗
SHIKARI®

Q-NIVO • S-ATN • S-ATN w/confirmation

NIVOLUMAB (Opdivo®) ELISA

Nivolumab is a fully human IgG4 antibody targeting the immune checkpoint programmed death receptor-1 (PD-1). Nivolumab is indicated to treat unresectable or metastatic melanoma, melanoma as adjuvant treatment, resectable or metastatic non-small cell lung cancer, small cell lung cancer, advanced renal cell carcinoma, classical Hodgkin lymphoma, squamous cell carcinoma of the head and neck, urothelial carcinoma, microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer, hepatocellular carcinoma, and esophageal cancer. The ligands PD-L1 and PD-L2 bind to the PD-1 receptor on T-cells, inhibiting the action of these cells. Tumor cells express PD-L1 and PD-L2. Nivolumab binds to PD-1, preventing PD-L1 and PD-L2 from inhibiting the action of T-cells, restoring a patient's tumor-specific T-cell response. Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary.

SHIKARI® Q-NIVO: Enzyme immunoassay for the quantitative determination of free Nivolumab (Opdivo®) in serum and plasma. This kit has been especially developed for the quantitative determination of Nivolumab in serum and plasma samples between the Cmin and Cmax range of concentrations.

SHIKARI® S-ATN: Enzyme immunoassay for the qualitative determination (screening) of antibodies to Nivolumab (Opdivo®) in serum and plasma. This kit has been especially developed for the quantitative determination of antibodies to Nivolumab in serum and plasma samples.

SHIKARI® S-ATN w/confirmation: Enzyme immunoassay for the quantitative determination (screening) of antibodies to Nivolumab (Opdivo®) in serum and plasma with confirmation. This kit has been especially developed for the quantitative determination of antibodies to Nivolumab in serum and plasma sample.

Shikari® (Q-NIVO) Nivolumab ELISA



Shikari® (S-ATN) Anti-Nivolumab ELISA w/confirmation



Catalog Number/Code	**Q-NIVO** NIV-FD-OPD	**S-ATN** NIV-QLS-OPD	**S-ATN w/confirmation** NIV-QNS-OPD
Required Volume (µl)	10	20	5
Total Time (min)	70	140	140
Sample	Serum, plasma	Serum, plasma	Serum, plasma
Sample Number	96	96	96
Detection Limit (ng/ml)	30	+ / -	20
Spike Recovery (%)	Between 85 - 115	-	Between 85 - 115
Shelf Life (year)	1	1	1
Assay Type	Quantitative	Qualitative	Quantitative
Species Reactivity	Human	Human	Human
Storage Conditions	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.
Shipping Conditions	At room temperature	At room temperature	At room temperature

OMALIZUMAB, 奥马珠单抗
SHIKARI®

Q-OMA • S-ATO

OMALIZUMAB (Xolair®) ELISA

Omalizumab is a recombinant, humanized, monoclonal antibody against human immunoglobulin E (IgE) which treats the symptoms of asthma and chronic idiopathic urticaria by limiting the allergic response. It inhibits the binding of IgE to receptors on mast cells and basophils, blocking the IgE-mediated secretion of inflammatory mediators from these cells. Mast cell activation and the release of mediators, in response to allergen exposure and IgE, results in a cascade of events. Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary.

SHIKARI® Q-OMA: Enzyme immunoassay for the quantitative determination of Omalizumab (Xolair®) in serum and plasma. This kit has been especially developed for the quantitative determination of Omalizumab in serum and plasma samples between the Cmin and Cmax range of concentrations.

SHIKARI® S-ATO: Enzyme immunoassay for the qualitative determination of specific antibodies to Omalizumab (Xolair®) in human serum and plasma. This kit has been especially developed for the qualitative determination of Omalizumab in serum and plasma samples.

Shikari® (Q-OMA) Omalizumab ELISA



Catalog Number/Code	**Q-OMA** OMA-FD-XOL	**S-ATO** OMA-QLS-XOL
Required Volume (µl)	10	20
Total Time (min)	70	140
Sample	Serum, plasma	Serum, plasma
Sample Number	96	96
Detection Limit (ng/ml)	10	+ / -
Spike Recovery (%)	Between 85 - 115	-
Shelf Life (year)	1	1
Assay Type	Quantitative	Qualitative
Species Reactivity	Human	Human
Storage Conditions	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.
Shipping Conditions	At room temperature	At room temperature

PALIVIZUMAB，帕利珠单抗
SHIKARI®

Q-PAL • S-ATPAL • S-ATPAL w/confirmation

PALIVIZUMAB (Synagis®) ELISA

Palivizumab is a monoclonal anti respiratory syncytial virus F protein antibody used to prevent serious sequelae caused by respiratory syncytial virus infection in pediatric patients. Humanized monoclonal antibody (IgG1k) produced by recombinant DNA technology, directed to an epitope in the A antigenic site of the F protein of respiratory syncytial virus (RSV). Synagis is a composite of human (95%) and murine (5%) antibody sequences. Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary.

SHIKARI® Q-PAL: Enzyme immunoassay for the quantitative determination of Palivizumab (Synagis®) in serum and plasma. This kit has been especially developed for the quantitative determination of Palivizumab in serum and plasma samples between the Cmin and Cmax range of concentrations.

SHIKARI® S-ATPAL: Enzyme immunoassay for the qualitative determination of specific antibodies to Palivizumab (Synagis®) in serum and plasma. This kit has been especially developed for the qualitative determination of specific antibodies to Palivizumab in serum and plasma samples.

SHIKARI® S-ATPAL w/confirmation: Enzyme immunoassay for the quantitative determination (screening) of antibodies to Palivizumab (Synagis®) in serum and plasma with confirmation. This kit has been especially developed for the quantitative determination of antibodies to Palivizumab in serum and plasma samples.

Shikari® (Q-PAL) Palivizumab ELISA



Shikari® (S-ATPAL) Anti-Palivizumab ELISA w/confirmation



Catalog Number/Code	**Q-PAL** PAL-FD-SYN	**S-ATPAL** PAL-QLS-SYN	**S-ATPAL w/confirmation** PAL-QNS-SYN
Required Volume (µl)	10	20	5
Total Time (min)	70	140	140
Sample	Serum, plasma	Serum, plasma	Serum, plasma
Sample Number	96	96	96
Detection Limit (ng/ml)	3	+ / -	18,75
Spike Recovery (%)	Between 85 - 115	-	Between 85 - 115
Shelf Life (year)	1	1	1
Assay Type	Quantitative	Qualitative	Quantitative
Species Reactivity	Human	Human	Human
Storage Conditions	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.
Shipping Conditions	At room temperature	At room temperature	At room temperature

PEMBROLIZUMAB, 帕博利珠单抗 SHIKARI®

Q-PEM • S-ATP • S-ATP w/confirmation

PEMBROLIZUMAB (Keytruda®) ELISA

Pembrolizumab is a PD-1 blocking antibody used to treat various types of cancer, including metastatic melanoma, non small-cell lung cancer, cervical cancer, head and neck cancer, and Hodgkin's lymphoma. As a highly selective IgG4-kappa humanized monoclonal antibody against PD-1 receptors, pembrolizumab binds with high affinity to the cell surface receptor programmed cell death protein 1 (PD-1) and antagonizes its interaction with its known ligands PD-L1 and PD-L2. The binding of pembrolizumab to PD-1 prevents this inhibitory pathway, causing a physiological shift towards immune reactivity and enhancing tumor immunosurveillance and anti-tumor immune response. Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary.

SHIKARI® Q-PEM: Enzyme immunoassay for the quantitative determination of free Pembrolizumab (Keytruda®) in serum and plasma. This kit has been especially developed for the quantitative determination of Pembrolizumab in serum and plasma samples between the Cmin and Cmax range of concentrations.

SHIKARI® S-ATP: Enzyme immunoassay for the qualitative determination (screening) of antibodies to Pembrolizumab (Keytruda®) in serum and plasma. This kit has been especially developed for the qualitative determination of antibodies to Pembrolizumab in serum and plasma samples.

SHIKARI® S-ATP w/confirmation: Enzyme immunoassay for the quantitative determination (screening) of antibodies to Pembrolizumab (Keytruda®) in serum and plasma with confirmation. This kit has been especially developed for the quantitative determination of antibodies to Pembrolizumab in serum and plasma samples.

Shikari® (Q-PEM) Pembrolizumab ELISA



Shikari® (S-ATP) Anti-Pembrolizumab ELISA w/confirmation



Catalog Number/Code	**Q-PEM** PEM-FD-KEY	**S-ATP** PEM-QLS-KEY	**S-ATP w/confirmation** PEM-QNS-KEY
Required Volume (µl)	10	20	20
Total Time (min)	140	140	140
Sample	Serum, plasma	Serum, plasma	Serum, plasma
Sample Number	96	96	96
Detection Limit (ng/ml)	10	+ / -	7,5
Spike Recovery (%)	Between 85 - 115	-	Between 85 - 115
Shelf Life (year)	1	1	1
Assay Type	Quantitative	Qualitative	Quantitative
Species Reactivity	Human	Human	Human
Storage Conditions	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.
Shipping Conditions	At room temperature	At room temperature	At room temperature

PERTUZUMAB, 帕妥珠单抗 SHIKARI®

Q-PER • S-ATPER

PERTUZUMAB (Perjeta®) ELISA

Pertuzumab is a recombinant humanized monoclonal antibody that targets the extracellular dimerization domain (subdomain II) of the human epidermal growth factor receptor 2 protein (HER2). It consists of two heavy chains and two lights chains that have 448 and 214 residues respectively. It was first approved by the FDA in 2012 for use with docetaxel and another HER2-targeted monoclonal antibody, trastuzumab, in the treatment of metastatic HER2- positive breast cancer. Its indicated conditions have since expanded to include use as both a neoadjuvant therapy and an adjuvant therapy in the treatment of HER2-positive breast cancers at high risk of recurrence. Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary.

SHIKARI® Q-PER: Enzyme immunoassay for the quantitative determination of Pertuzumab (Perjeta®) in human serum and plasma. This kit has been especially developed for the quantitative determination of Pertuzumab in serum and plasma samples between the Cmin and Cmax range of concentrations.

SHIKARI® S-ATPER: Enzyme immunoassay for the qualitative determination of specific antibodies to Pertuzumab (Perjeta®) in serum and plasma. This kit has been especially developed for the qualitative determination of specific antibodies to Pertuzumab in serum and plasma samples.

Shikari® (Q-PER) Pertuzumab ELISA



Catalog Number/Code	**Q-PER** PER-FD-PER	**S-ATPER** PER-QLS-PER
Required Volume (µl)	5	20
Total Time (min)	70	140
Sample	Serum, plasma	Serum, plasma
Sample Number	96	96
Detection Limit (ng/ml)	30	+ / -
Spike Recovery (%)	Between 85 - 115	-
Shelf Life (year)	1	1
Assay Type	Quantitative	Qualitative
Species Reactivity	Human	Human
Storage Conditions	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.
Shipping Conditions	At room temperature	At room temperature

RAMUCIRUMAB, 雷莫芦单抗 SHIKARI®

Q-RAM • S-ATRAM

RAMUCIRUMAB (Cyramza®) ELISA

Ramucirumab is an antineoplastic agent and direct VEGFR2 (vascular endothelial growth factor receptor 2) antagonist that blocks the binding of natural VEGF ligands, which are secreted by solid tumors to promote angiogenesis and enhance tumor blood supply. Ramucirumab is a human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor 2 (VEGFR2), a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells. By binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby preventing VEGF-stimulated receptor phosphorylation and downstream ligand-induced proliferation, permeability, and migration of human endothelial cells. Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary.

SHIKARI® Q-RAM: Enzyme immunoassay for the quantitative determination of specific Ramucirumab (Cyramza®) in serum and plasma. This kit has been especially developed for the quantitative determination of Ramucirumab (Cyramza®) in serum and plasma samples between the Cmin and Cmax range of concentrations.

SHIKARI® S-ATRAM: Enzyme immunoassay for the qualitative determination of specific antibodies to Ramucirumab (Cyramza®) in serum and plasma. This kit has been especially developed for the qualitative determination of specific antibodies to Ramucirumab in serum and plasma samples.

Shikari® (Q-RAM) Ramucirumab ELISA



Catalog Number/Code	**Q-RAM** RAM-FD-CYR	**S-ATRAM** RAM-QLS-CYR
Required Volume (µl)	10	20
Total Time (min)	70	140
Sample	Serum, plasma	Serum, plasma
Sample Number	96	96
Detection Limit (ng/ml)	5	+ / -
Spike Recovery (%)	Between 85 - 115	-
Shelf Life (year)	1	1
Assay Type	Quantitative	Qualitative
Species Reactivity	Human	Human
Storage Conditions	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.
Shipping Conditions	At room temperature	At room temperature

RANIBIZUMAB，雷珠单抗 SHIKARI®

Q-RAN

RANIBIZUMAB (Lucentis®) ELISA

Ranibizumab is a recombinant humanized monoclonal antibody and VEGF-A antagonist used for the management of macular edema after retinal vein occlusion, age-related macular degeneration (wet), and diabetic macular edema. Ranibizumab is a recombinant humanized IgG1 kappa isotype monoclonal antibody directed against human VEGF-A.5 Ranibizumab binds to VEGF-A with high affinity as well as its biologically active forms, such as VEGF165, VEGF121, and VEGF110. Ranibizumab binds to the receptor-binding site of VEGF-A, preventing it from binding to its receptors - VEGFR1 and VEGFR2 - that are expressed on the surface of endothelial cells. Ranibizumab thereby attenuates endothelial cell proliferation, vascular leakage, and new blood vessel formation. Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary.

SHIKARI® Q-RAN: Enzyme immunoassay for the quantitative determination of Ranibizumab (Lucentis®) in serum and plasma. This kit has been especially developed for the quantitative determination of Ranibizumab in serum and plasma samples between the Cmin and Cmax range of concentrations.

Shikari® (Q-RAN) Ranibizumab ELISA



Catalog Number/Code	**Q-RAN** RAN-FD-LUC
Required Volume (µl)	10
Total Time (min)	70
Sample	Aqueous Humour
Sample Number	96
Detection Limit (ng/ml)	0,625
Spike Recovery (%)	Between 85 - 115
Shelf Life (year)	1
Assay Type	Quantitative
Species Reactivity	Human
Storage Conditions	Store at +4°C. Please refer to protocols.
Shipping Conditions	At room temperature

RISANKIZUMAB, 瑞莎珠单抗
SHIKARI®

Q-RIS • S-ATRIS • S-ATRIS w/confirmation

RISANKIZUMAB (Skyrizi®) ELISA

Risankizumab is a fully humanized IgG1 monoclonal antibody (mAb) that is selective for interleukin 23 (IL-23). As an interleukin-23 antagonist, Risankizumab used to treat moderate to severe plaque psoriasis, active psoriatic arthritis, and moderately to severely active Crohn's disease in adults. Risankizumab acts to prevent the release of pro-inflammatory cytokines and chemokines that often lead to inflammatory skin symptoms, such as redness, pain, and plaques. Risankizumab binds with a high affinity to the p19 subunit of human interleukin 23 (IL-23) cytokine, thereby preventing its action on the IL-23 receptor. IL-23 is a cytokine released in the human body that is involved in inflammatory and immune processes, especially in peripheral tissues. Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary.

SHIKARI® Q-RIS: Enzyme immunoassay for the quantitative determination of free Risankizumab (Skyrizi®) in serum and plasma. This kit has been especially developed for the quantitative determination of Risankizumab in serum and plasma samples between the Cmin and Cmax range of concentrations.

SHIKARI® S-ATRIS: Enzyme immunoassay for the qualitative determination of antibodies to Risankizumab (Skyrizi®) in serum and plasma. This kit has been especially developed for the qualitative determination of antibodies to Risankizumab in serum and plasma.

SHIKARI® S-ATRIS w/confirmation: Enzyme immunoassay for the quantitative determination of antibodies to Risankizumab (Skyrizi®) in serum and plasma. This kit has been especially developed for the qualitative determination of antibodies to Risankizumab in serum and plasma.

Shikari® (Q-RIS) Risankizumab ELISA



Shikari® (S-ATRIS) Anti-Risankizumab ELISA w/confirmation



Catalog Number/Code	**Q-RIS** RIS-FD-SKY	**S-ATRIS** RIS-QLS-SKY	**S-ATRIS w/confirmation** RIS-QNS-SKY
Required Volume (µl)	5	20	20
Total Time (min)	70	140	140
Sample	Serum, plasma	Serum, plasma	Serum, plasma
Sample Number	96	96	96
Detection Limit (ng/ml)	3	+ / -	6,25
Spike Recovery (%)	Between 85 - 115	-	-
Shelf Life (year)	1	1	1
Assay Type	Quantitative	Qualitative	Quantitative
Species Reactivity	Human	Human	Human
Storage Conditions	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.
Shipping Conditions	At room temperature	At room temperature	At room temperature

RITUXIMAB，利妥昔单抗 SHIKARI®

Q-RITUX • S-ATR • S-ATR w/confirmation

RITUXIMAB (Rituxan®, Mabthera®) ELISA

Rituximab is a monoclonal anti-CD20 antibody used to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia, Wegener's granulomatosis, pemphigus vulgaris, and rheumatoid arthritis.

Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. Rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light and heavy-chain variable region sequences and human constant region sequences. Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary.

SHIKARI® Q-RITUX: Enzyme immunoassay for the quantitative determination of Rituximab (Rituxan®, Mabthera®) in human serum and plasma. This kit has been especially developed for the quantitative determination of Rituximab in serum and plasma samples between the Cmin and Cmax range of concentrations.

Shikari® (Q-RITUX) Rituximab ELISA



Catalog Number/Code	**Q-RITUX** RIT-FD-RM
Required Volume (µl)	10
Total Time (min)	135
Sample	Serum, plasma
Sample Number	96
Detection Limit (ng/ml)	3
Spike Recovery (%)	Between 85 - 115
Shelf Life (year)	1
Assay Type	Quantitative
Species Reactivity	Human
Storage Conditions	Store at +4°C. Please refer to protocols.
Shipping Conditions	At room temperature

RITUXIMAB, 利妥昔单抗 SHIKARI®

Q-RITUX • S-ATR • S-ATR w/confirmation

RITUXIMAB (Rituxan®, Mabthera®) ELISA

SHIKARI® S-ATR: Enzyme immunoassay for the qualitative determination of specific antibodies to of Rituximab (Rituxan®, Mabthera®) in serum and plasma. This kit has been especially developed for the qualitative determination of specific antibodies to Rituximab in serum and plasma samples.

SHIKARI® S-ATR w/confirmation: Enzyme immunoassay for the quantitative determination of antibodies to of Rituximab (Rituxan®, Mabthera®) in serum and plasma with confirmation. This kit has been especially developed for the quantitative antibodies to Rituximab in serum and plasma samples.

Shikari® (S-ATR) Anti-Rituximab ELISA w/confirmation



	S-ATR RIT-QLS-RM	S-ATR w/confirmation RIT-QNS-RM
Catalog Number/Code		
Required Volume (µl)	20	20
Total Time (min)	140	140
Sample	Serum, plasma	Serum, plasma
Sample Number	96	96
Detection Limit (ng/ml)	+ / -	7,5
Spike Recovery (%)	-	Between 85 - 115
Shelf Life (year)	1	1
Assay Type	Qualitative	Quantitative
Species Reactivity	Human	Human
Storage Conditions	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.
Shipping Conditions	At room temperature	At room temperature

SECUKINUMAB，司库奇尤单抗
SHIKARI®

Q-SEC • S-ATSEC

SECUKINUMAB (Verxant®) ELISA

Secukinumab is an immunomodulating agent and interleukin antagonist used to manage plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, along with other joint inflammatory disorders.Secukinumab is a fully human monoclonal IgG1/κ antibody against interleukin-17A (IL-17A), a proinflammatory cytokine implicated in various chronic immune-mediated inflammatory disorders, such as plaque psoriasis. Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary.

SHIKARI® Q-SEC: Enzyme immunoassay for the quantitative determination of Secukinumab (Cosentyx® Verxant®) in serum and plasma. This kit has been especially developed for the quantitative determination of Secukinumab in serum and plasma samples between the Cmin and Cmax range of concentrations.

SHIKARI® S-ATSEC: Enzyme immunoassay for the qualitative determination of specific antibodies to Secukinumab (Cosentyx® Verxant®) in serum and plasma. This kit has been especially developed for the qualitative determination of specific antibodies to Secukinumab in serum and plasma samples.

Shikari® (Q-SEC) Secukinumab ELISA



Catalog Number/Code	**Q-SEC** SEC-FD-VER	**S-ATSEC** SEC-QLS-VER
Required Volume (µl)	10	20
Total Time (min)	70	140
Sample	Serum, plasma	Serum, plasma
Sample Number	96	96
Detection Limit (ng/ml)	3	+ / -
Spike Recovery (%)	Between 85 - 115	-
Shelf Life (year)	1	1
Assay Type	Quantitative	Qualitative
Species Reactivity	Human	Human
Storage Conditions	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.
Shipping Conditions	At room temperature	At room temperature

TOCILIZUMAB, 托珠单抗 SHIKARI®

Q-TOC • S-ATOC • S-ATOC w/confirmation

TOCILIZUMAB (Actemra®) ELISA

Tocilizumab is an interleukin-6 (IL-6) receptor antagonist used to treat Cytokine Release Syndrome (CRS), Systemic Juvenile Idiopathic Arthritis (sJIA), Giant Cell Arteritis (GCA), and Rheumatoid Arthritis (RA). Tocilizumab binds soluble and membrane bound IL-6 receptors, preventing IL-6 mediated inflammation. Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary.

SHIKARI® Q-TOC: Enzyme immunoassay for the quantitative determination of Tocilizumab (Actemra®) in human serum and plasma. This kit has been especially developed for the quantitative determination of Tocilizumab in serum and plasma samples between the Cmin and Cmax range of concentrations.

SHIKARI® S-ATOC: Enzyme immunoassay for the qualitative determination of Tocilizumab (Actemra®) in human serum and plasma. This kit has been especially developed for the qualitative determination of Tocilizumab in serum and plasma samples.

SHIKARI® S-ATOC w/confirmation: Enzyme immunoassay for the quantitative determination of Tocilizumab (Actemra®) in human serum and plasma. This kit has been especially developed for the quantitative determination of Tocilizumab in serum and plasma samples.

Shikari® (Q-TOC) Tocilizumab ELISA



Shikari® (S-ATOC) Anti-Tocilizumab ELISA w/confirmation



Catalog Number/Code	**Q-TOC** TOC-FD-ACT	**S-ATOC** TOC-QLS-ACT	**S-ATOC w/confirmation** TOC-QNS-ACT
Required Volume (µl)	10	20	10
Total Time (min)	70	140	140
Sample	Serum, plasma	Serum, plasma	Serum, plasma
Sample Number	96	96	96
Detection Limit (ng/ml)	3	+ / -	5
Spike Recovery (%)	Between 85 - 115	-	Between 85 - 115
Shelf Life (year)	1	1	1
Assay Type	Quantitative	Qualitative	Quantitative
Species Reactivity	Human	Human	Human
Storage Conditions	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.
Shipping Conditions	At room temperature	At room temperature	At room temperature

TRASTUZUMAB, 曲妥珠单抗
SHIKARI®

Q-TRAS • S-ATT • S-ATT w/confirmation

TRASTUZUMAB (Herclon®, Herceptin®) ELISA

Trastuzumab is a monoclonal anti-human epidermal growth factor receptor 2 protein antibody used to treat HER2-positive breast, gastroesophageal, and gastric cancers. Produced in CHO cell cultures, trastuzumab is a recombinant IgG1 kappa, humanized monoclonal antibody that selectively binds with high affinity in a cell-based assay (Kd = 5 nM) to the extracellular domain of the human epidermal growth factor receptor protein (HER2).Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary.

SHIKARI® Q-TRAS: Enzyme immunoassay for the quantitative determination of Trastuzumab (Herceptin®, Herclon®)in human serum and plasma. This kit has been especially developed for the quantitative determination of Trastuzumab in serum and plasma samples between the Cmin and Cmax range of concentrations.

SHIKARI® S-ATT: Enzyme immunoassay for the qualitative determination of specific antibodies to Trastuzumab (Herceptin®, Herclon®) in serum and plasma. This kit has been especially developed for the qualitative determination of specific antibodies to Trastuzumab in serum and plasma samples.

SHIKARI® S-ATT w/confirmation: Enzyme immunoassay for the quantitative determination of antibodies to Trastuzumab (Herceptin®, Herclon®) in serum and plasma with confirmation. This kit has been especially developed for the quantitative antibodies to Trastuzumab in serum and plasma samples.

Shikari® (Q-TRAS) Trastuzumab ELISA



Shikari® (S-ATT) Anti-Trastuzumab ELISA w/confirmation



Catalog Number/Code	**Q-TRAS** TRA-FD-HH	**S-ATT** TRA-QLS-HH	**S-ATT w/confirmation** TRA-QNS-HH
Required Volume (µl)	10	20	20
Total Time (min)	70	140	140
Sample	Serum, plasma	Serum, plasma	Serum, plasma
Sample Number	96	96	96
Detection Limit (ng/ml)	3	+ / -	7,5
Spike Recovery (%)	Between 85 - 115	-	Between 85 - 115
Shelf Life (year)	1	1	1
Assay Type	Quantitative	Qualitative	Quantitative
Species Reactivity	Human	Human	Human
Storage Conditions	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.
Shipping Conditions	At room temperature	At room temperature	At room temperature

USTEKINUMAB，乌司奴单抗
SHIKARI®

Q-UST • QS-UST • S-ATU • S-ATU w/confirmation

USTEKINUMAB (Stelara®) ELISA

Ustekinumab is a targeted antibody therapy used to manage inflammatory conditions such as plaque psoriasis, psoriatic arthritis, Crohn's Disease, and ulcerative colitis. Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses.

SHIKARI® Q-UST: Enzyme immunoassay for the quantitative determination of Ustekinumab (Stelara®) in serum and plasma. This kit has been especially developed for the quantitative determination of Ustekinumab in serum and plasma samples between the Cmin and Cmax range of concentrations.

SHIKARI® QS-USTEKINUMAB: Ustekinumab ELISA has been especially developed for the specific and quantitative analysis of free Ustekinumab in serum and plasma samples.

Shikari® (Q-UST) Ustekinumab ELISA



Shikari® (QS-UST) Ustekinumab ELISA



Catalog Number/Code	**Q-UST** UST-FD-STE	**QS-UST** UST-SPEC-UST
Required Volume (µl)	10	10
Total Time (min)	70	70
Sample	Serum, plasma	Serum, plasma
Sample Number	96	96
Detection Limit (ng/ml)	2,5	2,34
Spike Recovery (%)	Between 85 - 115	Between 85 - 115
Shelf Life (year)	1	1
Assay Type	Quantitative	Quantitative
Species Reactivity	Human	Human
Storage Conditions	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.
Shipping Conditions	At room temperature	At room temperature

USTEKINUMAB，乌司奴单抗 SHIKARI®

Q-UST • QS-UST • S-ATU • S-ATU w/confirmation

USTEKINUMAB (Stelara®) ELISA

SHIKARI® S-ATU: Enzyme immunoassay for the qualitative determination of antibodies to Ustekinumab (Stelara®) in serum and plasma. This kit has been especially developed for the qualitative determination of antibodies to Ustekinumab in serum and plasma samples.

SHIKARI® S-ATU w/confirmation: Enzyme immunoassay for the quantitative determination of antibodies to Ustekinumab (Stelara®) in serum and plasma. This kit has been especially developed for the quantitative determination of antibodies to Ustekinumab in serum and plasma samples.

Shikari® (S-ATU) Anti-Ustekinumab ELISA w/confirmation



Catalog Number/Code	S-ATU UST-QLS-STE	S-ATU w/confirmation UST-QNS-STE
Required Volume (µl)	20	20
Total Time (min)	140	140
Sample	Serum, plasma	Serum, plasma
Sample Number	96	96
Detection Limit (ng/ml)	+ / -	7,5
Spike Recovery (%)	-	Between 85 - 115
Shelf Life (year)	1	1
Assay Type	Qualitative	Quantitative
Species Reactivity	Human	Human
Storage Conditions	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.
Shipping Conditions	At room temperature	At room temperature

VEDOLIZUMAB，维多珠单抗 SHIKARI®

Q-VEDO • S-ATV • S-ATV w/confirmation

VEDOLIZUMAB (Entyvio®) ELISA

Vedolizumab is an integrin blocker and anti-inflammatory agent used to manage ulcerative colitis and Crohn's disease in adults with inadequate clinical response to immunomodulators.Vedolizumab is a recombinant humanized IgG1 monoclonal antibody directed against the human lymphocyte α4ß7 integrin, a key mediator of gastrointestinal inflammation. It is used in the treatment of moderate to severe active ulcerative colitis and Crohn's disease for patients who have had an inadequate response with, lost response to, or were intolerant to inhibitors of tumor necrosis factor-alpha (TNF-alpha) or other conventional therapies.

SHIKARI® Q-VEDO: Enzyme immunoassay for the quantitative determination of Vedolizumab (Entyvio®) in serum and plasma. This kit has been especially developed for the quantitative determination of Vedolizumab in serum and plasma samples between the Cmin and Cmax range of concentrations.

SHIKARI® QS-VEDO: Vedolizumab ELISA has been especially developed for the specific and quantitative analysis of free Vedolizumab in serum and plasma samples.

Shikari® (Q-VEDO) Vedolizumab ELISA



Shikari® (QS-VEDO) Vedolizumab ELISA



Catalog Number/Code	Q-VEDO VED-FD-ENT	QS-VEDO VED-SPEC-VED
Required Volume (µl)	10	10
Total Time (min)	100	70
Sample	Serum, plasma	Serum, plasma
Sample Number	96	96
Detection Limit (ng/ml)	1,56	1
Spike Recovery (%)	Between 85 - 115	Between 85 - 115
Shelf Life (year)	1	1
Assay Type	Quantitative	Quantitative
Species Reactivity	Human	Human
Storage Conditions	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.
Shipping Conditions	At room temperature	At room temperature

VEDOLIZUMAB, 维多珠单抗
SHIKARI®

Q-VEDO • QS-VEDO • S-ATV • S-ATV w/confirmation

VEDOLIZUMAB (Entyvio®) ELISA

SHIKARI® S-ATV: Enzyme immunoassay for the qualitative determination of antibodies to Vedolizumab (Entyvio®) in serum and plasma. This kit has been especially developed for the qualitative determination of antibodies to Vedolizumab in serum and plasma samples.

SHIKARI® S-ATV w/confirmation: Enzyme immunoassay for the quantitative determination of antibodies to Vedolizumab (Entyvio®) in serum and plasma. This kit has been especially developed for the quantitative determination of antibodies to Vedolizumab in serum and plasma samples.

Shikari® (S-ATV) Anti-Vedolizumab ELISA w/confirmation



Catalog Number/Code	**S-ATV** VED-QLS-ENT	**S-ATV w/confirmation** VED-QNS-ENT
Required Volume (µl)	20	20
Total Time (min)	140	140
Sample	Serum, plasma	Serum, plasma
Sample Number	96	96
Detection Limit (ng/ml)	+ / -	7,5
Spike Recovery (%)	-	Between 85 - 115
Shelf Life (year)	1	1
Assay Type	Qualitative	Quantitative
Species Reactivity	Human	Human
Storage Conditions	Store at +4°C. Please refer to protocols.	Store at +4°C. Please refer to protocols.
Shipping Conditions	At room temperature	At room temperature

系列	货号	描述		样本	方法
Shikari® (Q-ABA)	ABA-FD-ORE	Abatacept (Orencia®)	Free drug	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATAB)	ABA-QLS-ORE	Abatacept (Orencia®)	Antibody screening - Qualitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATAB)	ABA-QNS-ORE	Abatacept (Orencia®)	Antibody screening - Quantitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (Q-ADA)	ADA-FD-HUM	Adalimumab (Humira®)	Free drug	Serum/Plasma	Enzyme Immunoassay
Shikari® (QS-ADA)	ADA-SPEC-ADA	Adalimumab (Humira®)	Free drug/Specific and Quantitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATA)	ADA-QLS-HUM	Adalimumab (Humira®)	Antibody screening - Qualitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATA)	ADA-QNS-HUM	Adalimumab (Humira®)	Antibody screening - Quantitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATA)	ADA-QNFT-HUM	Adalimumab (Humira®)	Antibody screening - Free/Total semiquantitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (Q-AF)	AFL-FD-EYL	Aflibercept (Eylea®)	Free drug	Serum/Plasma	Enzyme Immunoassay
Shikari® (Q-AF) High Sensitive	AFL-FD-SENS-EYL	Aflibercept (Eylea®)	Free drug	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATAF)	AFL-QLS-EYL	Aflibercept (Eylea®)	Antibody screening - Qualitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATAF)	AFL-QNS-EYL	Aflibercept (Eylea®)	Antibody screening - Quantitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (Q-ATE)	ATE-FD-TEC	Atezolizumab (Tecentriq®)	Free drug	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATAT)	ATE-QLS-TEC	Atezolizumab (Tecentriq®)	Antibody screening - Qualitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (Q-AVE)	AVE-FD-BAV	Avelumab (Bavencio®)	Free drug	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATAV)	AVE-QLS-BAV	Avelumab (Bavencio®)	Antibody screening - Qualitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (Q-BEVA)	BEV-FD-AA	Bevacizumab (Avastin®)	Free drug	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATB)	BEV-QLS-AA	Bevacizumab (Avastin®)	Antibody screening - Qualitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATB)	BEV-QNS-AA	Bevacizumab (Avastin®)	Antibody screening - Quantitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (Q-CAN)	CAN-FD-ILA	Canakinumab (Ilaris®)	Free drug	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATCAN)	CAN-QLS-ILA	Canakinumab (Ilaris®)	Antibody screening - Qualitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATCAN)	CAN-QNS-ILA	Canakinumab (Ilaris®)	Antibody screening - Quantitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (Q-CERT)	CER-FD-CIM	Certolizumab (Cimzia®)	Free drug	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATCER)	CER-QNS-CIM	Certolizumab (Cimzia®)	Antibody screening - Quantitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (Q-CET)	CET-FD-ERB	Cetuximab (Erbitux®)	Free drug	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATC)	CET-QLS-ERB	Cetuximab (Erbitux®)	Antibody screening - Qualitative	Serum/Plasma	Enzyme Immunoassay

Shikari® (S-ATC)	CET-QNS-ERB	Cetuximab (Erbitux®)	Antibody screening - Quantitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (Q-DAR)	DAR-FD-DAR	Daratumumab (Darzalex®)	Free drug	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATDAR)	DAR-QLS-DAR	Daratumumab (Darzalex®)	Antibody screening - Qualitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (Q-DEN)	DEN-FD-PRO	Denosumab (Prolia®)	Free drug	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATD)	DEN-QLS-PRO	Denosumab (Prolia®)	Antibody screening - Qualitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATD)	DEN-QNS-PRO	Denosumab (Prolia®)	Antibody screening - Quantitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (Q-DUR)	DUR-FD-IMF	Durvalumab (Imfinzi®)	Free drug	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATDUR)	DUR-QLS-IMF	Durvalumab (Imfinzi®)	Antibody screening - Qualitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (Q-ECU)	ECU-FD-SOL	Eculizumab (Solaris®)	Free drug	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATEC)	ECU-QLS-SOL	Eculizumab (Solaris®)	Antibody screening - Qualitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATEC)	ECU-QNS-SOL	Eculizumab (Solaris®)	Antibody screening - Quantitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (Q-ETA)	ETA-FD-ENB	Etanercept (Enbrel®)	Free drug	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATE)	ETA-QLS-ENB	Etanercept (Enbrel®)	Antibody screening - Qualitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (Q-EVO)	EVO-FD-REP	Evolocumab (Repatha®)	Free drug	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATEVO)	EVO-QLS-REP	Evolocumab (Repatha®)	Antibody screening - Qualitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (Q-AFA)	FIL-QNS-FRA	Filgrastim	Antibody screening - Quantitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (Q-GOL)	GOL-FD-SIM	Golimumab (Simponi®)	Free drug	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATG)	GOL-QLS-SIM	Golimumab (Simponi®)	Antibody screening - Qualitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATG)	GOL-QNS-SIM	Golimumab (Simponi®)	Antibody screening - Quantitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (Q-INFLIXI)	INF-FD-REMI	Infliximab (Remicade®)	Free drug	Serum/Plasma	Enzyme Immunoassay
Shikari® (QS-INFLIXI)	INF-SPEC-INF	Infliximab (Remicade®)	Free drug/Specific and Quantitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (Q-ATI)	INF-QLS-REMI	Infliximab (Remicade®)	Antibody screening - Qualitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (Q-ATI)	INF-QNS-REMI	Infliximab (Remicade®)	Antibody screening - Quantitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (Q-ATIDUO)	INF-QNFT-REMI	Infliximab (Remicade®)	Antibody screening - Free/Total semiquantitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (Q-REMS)	INF-FD-REMS	Infliximab (Remsima®)	Free drug	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-AIR)	INF-QLS-REMS	Infliximab (Remsima®)	Antibody screening - Qualitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-AIR)	INF-QNS-REMS	Infliximab (Remsima®)	Antibody screening - Quantitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-AIR)	INF-QNFT-REMS	Infliximab (Remsima®)	Antibody screening - Total semiquantitative	Serum/Plasma	Enzyme Immunoassay

Shikari® (Q-IPI)	IPI-FD-YER	Ipilimumab (Yervoy®)	Free drug	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATI)	IPI-QLS-YER	Ipilimumab (Yervoy®)	Antibody screening - Qualitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATI)	IPI-QNS-YER	Ipilimumab (Yervoy®)	Antibody screening- Quantitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (Q-IXE)	IXE-FD-TAL	Ixekizumab (Taltz®)	Free drug	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATIXE)	IXE-QLS-TAL	Ixekizumab (Taltz®)	Antibody screening - Qualitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (Q-NAT)	NAT-FD-TYS	Natalizumab (Tysabri®)	Free drug	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATNAT)	NAT-QLS-TYS	Natalizumab (Tysabri®)	Antibody screening - Qualitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATNAT)	NAT-QNS-TYS	Natalizumab (Tysabri®)	Antibody screening - Quantitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (Q-NIVO)	NIV-FD-OPD	Nivolumab (Opdivo®)	Free drug	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATN)	NIV-QLS-OPD	Nivolumab (Opdivo®)	Antibody screening - Qualitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATN)	NIV-QNS-OPD	Nivolumab (Opdivo®)	Antibody screening- Quantitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (Q-OMA)	OMA-FD-XOL	Omalizumab (Xolair®)	Free drug	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATO)	OMA-QLS-XOL	Omalizumab (Xolair®)	Antibody screening - Qualitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (Q-PAL)	PAL-FD-SYN	Palivizumab (Synagis®)	Free drug	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATPAL)	PAL-QLS-SYN	Palivizumab (Synagis®)	Antibody screening - Qualitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATPAL)	PAL-QNS-SYN	Palivizumab (Synagis®)	Antibody screening - Quantitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (Q-PEM)	PEM-FD-KEY	Pembrolizumab (Keytruda®)	Free drug	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATP)	PEM-QLS-KEY	Pembrolizumab (Keytruda®)	Antibody screening - Qualitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATP)	PEM-QNS-KEY	Pembrolizumab (Keytruda®)	Antibody screening - Quantitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (Q-PER)	PER-FD-PER	Pertuzumab (Perjeta®)	Free drug	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATPER)	PER-QLS-PER	Pertuzumab (Perjeta®)	Antibody screening - Qualitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (Q-RAM)	RAM-FD-CYR	Ramucirumab (Cyramza®)	Free drug	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATRAM)	RAM-QLS-CYR	Ramucirumab (Cyramza®)	Antibody screening - Qualitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (Q-RAN)	RAN-FD-LUC	Ranibizumab (Lucentis®)	Free drug	Aqueous Humour	Enzyme Immunoassay
Shikari® (Q-RIS)	RIS-FD-SKY	Risankizumab (Skyrizi®)	Free drug	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATRIS)	RIS-QLS-SKY	Risankizumab (Skyrizi®)	Antibody screening - Qualitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATRIS)	RIS-QNS-SKY	Risankizumab (Skyrizi®)	Antibody screening - Quantitative	Serum/Plasma	Enzyme Immunoassay

Shikari® (Q-RITUX)	RIT-FD-RM	Rituximab (Rituxan®, Mabthera®)	Free drug	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATR)	RIT-QLS-RM	Rituximab (Rituxan®, Mabthera®)	Antibody screening - Qualitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATR)	RIT-QNS-RM	Rituximab (Rituxan®, Mabthera®)	Antibody screening - Quantitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (Q-SEC)	SEC-FD-VER	Secukinumab (Cosentyx® , Verxant®)	Free drug	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATSEC)	SEC-QLS-VER	Secukinumab (Cosentyx® , Verxant®)	Antibody screening - Qualitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (Q-TOC)	TOC-FD-ACT	Tocilizumab (Actemra®)	Free drug	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATOC)	TOC-QLS-ACT	Tocilizumab (Actemra®)	Antibody screening - Qualitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATOC)	TOC-QNS-ACT	Tocilizumab (Actemra®)	Antibody screening - Quantitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (Q-TRAS)	TRA-FD-HH	Trastuzumab (Herceptin®, Herclon®)	Free drug	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATT)	TRA-QLS-HH	Trastuzumab (Herceptin®, Herclon®)	Antibody screening - Qualitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATT)	TRA-QNS-HH	Trastuzumab (Herceptin®, Herclon®)	Antibody screening - Quantitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (Q-UST)	UST-FD-STE	Ustekinumab (Stelara®)	Free drug	Serum/Plasma	Enzyme Immunoassay
Shikari® (QS-UST)	UST-SPEC-UST	Ustekinumab (Stelara®)	Free drug/Specific and Quantitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATU)	UST-QLS-STE	Ustekinumab (Stelara®)	Antibody screening - Qualitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATU)	UST-QNS-STE	Ustekinumab (Stelara®)	Antibody screening - Quantitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (Q-VEDO)	VED-FD-ENT	Vedolizumab (Entyvio®)	Free drug	Serum/Plasma	Enzyme Immunoassay
Shikari® (QS-VEDO)	VED-SPEC-VED	Vedolizumab (Entyvio®)	Free drug/Specific and Quantitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATV)	VED-QLS-ENT	Vedolizumab (Entyvio®)	Antibody screening - Qualitative	Serum/Plasma	Enzyme Immunoassay
Shikari® (S-ATV)	VED-QNS-ENT	Vedolizumab (Entyvio®)	Antibody screening - Quantitative	Serum/Plasma	Enzyme Immunoassay

合作单位



Matriks 中国区总代理，艾美捷科技，400-6800-868

合作单位


A.MENARINI
diagnostics


université
de BORDEAUX


Einstein
HEALTHCARE NETWORK
More than Medicine


自主創造
日本大学
NIHON UNIVERSITY


LUPIN
PHARMACEUTICALS, INC.


SANDOZ


SQI


PROTALIX
Biotherapeutics


prospecta


YOUNG IN FRONTIER


ISCARE


UZ
LEUVEN


maccine


QPS
helps you navigate


SUNG KYUN KWAN
UNIVERSITY


ANKARA ÜNİVERSİTESİ
1946


MEDICAL
UNIVERSITY
OF VIENNA


Reliance
LIFE SCIENCES


teva


UNIVERSITAS COMENIANA BRATISLAVENSIS
FACULTAS MEDICA
MCMXIX


MERCK


MOUNT
SINAI
HOSPITAL


SEJINBIOTECH CO., LTD


TriChem ApS
interkemi


Shigematsu co.,Ltd
重松貿易株式会社


METU


Western
UNIVERSITY · CANADA


SINAPHARM
THE HEALTH EXPERTS


TRITEC Systems Ltd.


nacalai tesque
The quality for certainty.


Medix
Biochemica


Hospital General
Universitari d'Alacant


OUH
Odense
Universitetshospital


Universitat d'Alacant
Universidad de Alicante


UR
Universität Regensburg


T.C. İSTANBUL ÜNİVERSİTESİ
1453


浜松医科大学
Hamamatsu University School of Medicine


UNIVERSITÀ DEGLI STUDI
DI GENOVA

isc
Instituto de Salud Carlos III

SAMSUNG
SAMSUNG MEDICAL CENTER

UniversitätsSpital
Zürich

MEDICAL UNIVERSITY
OF VIENNA

ROYAL NORTH SHORE
HOSPITAL

PharmaNet

KU MC
KOREA
UNIVERSITY
MEDICAL CENTER

UNIVERSITY
of
OTAGO
Te Whare Wānanga o Otāgo
NEW ZEALAND

UNIVERSITÄT
LEIPZIG

UNIVERZITNÁ
NEMOCNICA
BRATISLAVA

慶應義塾
Keio University

UNIVERSITAS SCIENTIARUM SZEGEDIENSIS
SZEGEDI TUDOMÁNYEGYETEM

KATHOLIEKE UNIVERSITEIT
LEUVEN

PROMETHEUS
Therapeutics & Diagnostics

CHARLES
UNIVERSITY

INDIANA UNIVERSITY
SCHOOL OF MEDICINE

bioAzure
Technologies Pvt. Ltd.

(주)프로팜텍
PROPHARMTECH Co., Ltd.

JIMRO

LabTech

发表文章

PUBLICATIONS	INSTITUTES	PRODUCTS
Peña-Cabia, Silvia, et al. "Assessment of exposure-response relationship for cetuximab in patients with metastatic colorectal cancer and head and neck cancer." Farmacia Hospitalaria: Organo Oficial de Expresion Cientifica de la Sociedad Espanola de Farmacia Hospitalaria 46.1 (2021): 21-26.	Pharmacy Unit, Severo Ochoa University Hospital, Madrid, Spain	CET-FD-ERB
Guven, Deniz Can, et al. "Immunogenicity of two doses of inactive COVID-19 vaccine and third booster dose mRNA vaccine in patients with cancer receiving active systemic therapy." International Journal of Cancer (2022).	Hacettepe University Cancer Institute, Department of Medical Oncology, Ankara, Turkey.	COR-QNS-IGG-SRBD
Liu, Zheng, et al. "Timing of live attenuated vaccination in infants exposed to infliximab or adalimumab in utero: A prospective cohort study in 107 children." Journal of Crohn's and Colitis (2022).	Clinical Pharmacology, School of Medicine and Public Health, University of Newcastle, Hunter Medical Research Institute, Kookaburra Circuit, Australia.	INF-FD-REMI ADA-FD-HUM
Kita, Toshihiro, et al. "Adrenomedullin for biologic-resistant Crohn's disease: A randomized, double-blind, placebo-controlled phase 2a clinical trial." Journal of Gastroenterology and Hepatology (2022).	Division of Gastroenterology and Hepatology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki	INF-FD-REMI ADA-FD-HUM
Iwasaki, Takeshi, et al. "Dynamics of type I and type II interferon signature determines responsiveness to anti-TNF therapy in rheumatoid arthritis." Frontiers in immunology 13 (2022).	Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan.	INF-FD-REMI ADA-FD-HUM ETA-FD-ENB INF-QNS-REMI ADA-QNS-HUM ETA-QLS-ENB
Cantarelli, Lorenzo, et al. "Definition of a therapeutic range for predicting long-term infliximab response in patients with inflammatory bowel disease." Medicina Clínica (2022).	Servicio de Farmacia. Complejo Hospitalario Universitario de Canarias, Tenerife, Spain.	INF-FD-REMI
Kawamoto, Ami, et al. "Serum Levels of Infliximab Biosimilar in a Child Delivered From a Mother Treated for Ulcerative Colitis." Inflammatory Bowel Diseases 28.8 (2022): 1298-1299.	Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University, Tokyo, Japan.	INF-FD-REMI
Sinha, Aditi, et al. "Sequential rituximab therapy sustains remission of nephrotic syndrome, but carries high risk of adverse effects." Nephrology Dialysis Transplantation (2022).	Division of Nephrology and ICMR Center for Advanced Research in Nephrology, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India.	RIT-FD-RM
Chen, Yewei, et al. "Population Pharmacokinetics of Rituximab in Pediatric Patients With Frequent-Relapsing or Steroid-Dependent Nephrotic Syndrome." Frontiers in Pharmacology (2021): 2348.	Department of Pharmacy, Children's Hospital of Fudan University, Shanghai, China	RIT-FD-RM
Linares, Raquel, et al. "Transcriptional regulation of chemokine network by biologic monotherapy in ileum of patients with Crohn's disease." Biomedicine & Pharmacotherapy 147 (2022): 112653.	Hepatic and Intestinal Immunobiology Group, Departamento Medicina Clínica, Universidad Miguel Hernandez, Spain	ADA-FD-HUM
Kim, Eun Sil, et al. "Albumin-to-Globulin Ratio at 1 Year after Anti-Tumor Necrosis Factor α Therapy Can Serve as a Prognostic Biomarker in Pediatric Crohn's Disease Patients." Gut and Liver 16.1 (2022): 71.	Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea	ADA-FD-HUM
Orts, Beatriz, et al. "Clinical and Immunological Factors Associated with Recommended Trough Levels of Adalimumab and Infliximab in Patients with Crohn's Disease." Frontiers in pharmacology 12 (2021): 795272-795272.	Unidad de Farmacología Clínica, Hospital General Universitario de Alicante, Alicante, Spain	ADA-FD-HUM INF-FD-REMI ADA-QNS-HUM INF-QNS-HUM
Pękala, Anna, and Rafał Filip. "Levels of Biosimilar Infliximab during and after Induction Treatment in Crohn's Disease and Ulcerative Colitis—A Prospective Polish Population Study." Journal of Clinical Medicine 10.22 (2021): 5311.	Department of Gastroenterology with IBD, Unit of Clinical Hospital 2 in Rzeszow, Rzeszow, Poland	INF-FD-REMS
MOHSEN, ENAS RIYADH, and NAAEL H. ALI. "IMPACT OF TH17/TREGFOXP3 CELLS RATIO ON RHEUMATOID ARTHRITIS PATIENTS RECEIVING ANTI TNF-THERAPY-." Journal of Duhok University 24.2 (2021): 90-102.APA	College of Medicine, University of Basrah-Iraq	ETA-QLS-ENB INF-QLS-REMI
De Gregorio, Michael, et al. "Higher Anti-tumor Necrosis Factor-α Levels Correlate With Improved Radiologic Outcomes in Crohn's Perianal Fistulas." Clinical Gastroenterology and Hepatology (2021).	St Vincent's Hospital Melbourne, Department of Gastroenterology, Fitzroy, Australia	ADA-FD-HUM INF-FD-REMI/ REMS
Нуриахметова, Т. Ю., et al. "Особенности ответа на инфликсимаб пациентов с воспалительными заболеваниями кишечника и анкилозирующим спондилитом." Русский медицинский журнал. Медицинское обозрение 5.2 (2021): 64-70.	FSBEI HE Kazan State Medical University of the Ministry of Health of Russia, Kazan, Russia	INF-FD-REMI INF-QLS-REMI INF-QNS-REMI

发表文章

Liu, Shu, et al. "Rituximab exposure-response in triweekly R-CHOP treatment in DLBCL: A loading dose is recommended to improve clinical outcomes." Clinical and Translational Science (2021).	State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China	RIT-FD-RM
Patil, A., Upadhyaya, S., Dawar, R., Dadhaniya, N., Sood, I., Gupta, S. J., Handa, R. Anti-drug antibodies and low serum trough infliximab levels correlate with disease activity measures in spondyloarthritis patients on an as-needed infliximab treatment. International Journal of Rheumatic Diseases (2019)	Department of Rheumatology, Indraprastha Apollo Hospitals, Delhi, India	INF-FD-REMI INF-QLS-REMI
Yang Wu, et al., Management Decisions in Crohn's Disease Are Changed by Knowledge of Proactive and Reactive Testing of Antitumor Necrosis Factor Drug Levels, Crohn's & Colitis 360, Volume 3, Issue 3, (2021)	Department of Gastroenterology and Hepatology, Liverpool Hospital, Sydney, New South Wales, Australia	ADA-FD-HUM INF-FD-REMI ADA-QNS-HUM INF-QNS-REMI
Tae Jong Jeong, Eun Sil Kim et al. Discontinuation of Azathioprine Could Be Considered in Pediatric Patients with Crohn's Disease who Have Sustained Clinical and Deep Remission, Scientific Reports (2021)	Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine	INF-FD-REMI
Pękala, Anna, and Rafał Filip. "Anti-Drug Antibodies in Patients with Inflammatory Bowel Diseases Treated with Biosimilar Infliximab: A ProspectiveCohort Study" Journal of Clinical Medicine (2021)	Department of Gastroenterology with IBD, Unit of Clinical Hospital 2 in Rzeszow, Rzeszow, Poland	ADA-FD-HUM INF-FD-REMS
Alañón Pardo, M. M., et al. "Monitorización farmacocinética de terapias biológicas en enfermedad inflamatoria intestinal." Revista de la OFIL 31.1 (2021): 49-57.	Hospital General La Mancha – Centro (Alcázar de San Juan). Ciudad Real, Spain	ADA-QLS-HUM INF-QLS-REMI ADA-QNS-HUM INF-QNS-REMI
Little, Robert D., et al. "De-escalation from Dose-Intensified Anti-TNF Therapy Is Successful in the Majority of IBD Patients at 12 Months." Digestive Diseases and Sciences (2021): 1-4.	Department of Gastroenterology, Alfred Health and Monash University, Melbourne 3004, Australia	ADA-FD-HUM INF-FD-REMI
Kim, Mi Jin, et al. "Therapeutic Drug Monitoring of Adalimumab During Long-term Follow-up in Paediatric Patients With Crohn Disease." Journal of Pediatric Gastroenterology and Nutrition 72.6 (2021): 870-876.	Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul.	ADA-FD-HUM
Ward, Mark G., et al. "Comparison of Sb2-Infliximab with Originator-Infliximab in the Measurement of Serum Concentrations A Short Communication." Therapeutic Drug Monitoring (2021).	Department of Gastroenterology, Alfred Hospital and Monash University, Melbourne, Victoria	INF-FD-REMI
Mocenigo, Marco, et al. "Rapid, Cost-Effective Peptide/ Nucleic Acid-Based Platform for Therapeutic Antibody Monitoring in Clinical Samples." ACS sensors 5.10 (2020): 3109-3115.	Ulisse BioMed Labs, Area Science Park, SS 14, km 163.5, 34149 Trieste, Italy Molecular Genetics and Biotechnology PhD study programme, University of Nova Gorica, Vipavska 13, Nova Gorica, Slovenia	TRA-FD-HH
Judit Szántó, Kata, et al. "Advances in the optimisation of therapeutic drug monitoring using serum, tissue and faecal anti-tumour necrosis factor concentration in patients with inflammatory bowel disease treated with TNF-antagonists." Expert Opinion on Biological Therapy (2021).	Department of Medicine of Szeged, Szeged, Hungary.	ADA-FD-HUM INF-FD-REMI ADA-QNS-HUM INF-QNS-REM
Esatoglu, Sinem Nihal, et al. "Immunogenicity of Infliximab Among Patients With Behçet Syndrome: A Controlled Study." Frontiers in Immunology 11 (2020): 3378.	Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey	INF-FD-REMI INF-QNS-REMI
Padrón, Ivette Mourani, et al. "Anti-drug antibodies anti-trastuzumab in the treatment of breast cancer." Journal of Oncology Pharmacy Practice (2020): 1078155220953873.	Fundación Canaria Instituto de Investigación Sanitaria de Canarias, Complejo Hospitalario Universitario de Canarias, San Cristóbal de La Laguna, Santa Cruz de Tenerife, Spain.	TRA-QLS-HH
Luber, Raphael P., et al. "Thiopurines and their optimization during infliximab induction and maintenance: A retrospective study in Crohn's disease." Journal of Gastroenterology and Hepatology (2020).	Department of Gastroenterology, Alfred Hospital, Department of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Victoria	INF-FD-REMI INF-QNS-REMI
Formica, María Lina, et al. "Novel hybrid lipid nanocapsules loaded with a therapeutic monoclonal antibody–Bevacizumab–and Triamcinolone acetonide for combined therapy in neovascular ocular pathologies." Materials Science and Engineering: C 119 (2020): 111398.	Departamento de Farmacia, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Ciudad Universitaria, 5000 Córdoba, Argentina.	BEV-FD-AA
Zhang, Jinhua, et al. "sRNA-based screening chromosomal gene targets and modular designing Escherichia coli for high-titer production of aglycosylated immunoglobulin G." ACS Synthetic Biology (2020).	Frontier Science Center for Synthetic Biology, Key Laboratory of Systems Bioengineering (MOE), Collaborative Innovation Centre of Chemical Science and Engineering (Tianjin), and School of Chemical Engineering and Technology, Tianjin University, Tianjin 300350, P. R. China	CET-FD-ERB

发表文章

Yokoyama, Yoko, et al. "Efficacy of Granulocyte and Monocyte Adsorptive Apheresis in Patients with Inflammatory Bowel Disease Showing Lost Response to Infliximab." Journal of Crohn's and Colitis (2020).	Division of Internal Medicine, Department of Inflammatory Bowel Disease, Hyogo College of Medicine, Hyogo, Japan.	INF-QNS-REMI
Sureda, Manuel, et al. "Therapeutic drug monitoring of nivolumab in routine clinical practice. A pilot study." Farmacia Hospitalaria: Organo Oficial de Expresion Cientifica de la Sociedad Espanola de Farmacia Hospitalaria 44.3 (2020): 81-86.	Plataforma de Oncología, Hospital Quironsalud Torrevieja. 03184 Torrevieja (Alicante), España.	NIV-FD-OPD
Seong, Gyeol, et al. "Changes in the Intestinal Microbiota of Patients with Inflammatory Bowel Disease with Clinical Remission during an 8-Week Infliximab Infusion Cycle." Microorganisms 8.6 (2020): 874.	Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 135-710, Korea	INF-FD-REMI
Nieto, Juan C., et al. "Posttransplant cyclophosphamide after allogeneic hematopoietic cell transplantation mitigates the immune activation induced by previous nivolumab therapy." Leukemia (2020): 1-6.	Laboratory of Experimental Hematology, Department of Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital (HUVH), Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain.	NIV-FD-OPD
Liu, Shu, et al. "Low initial trough concentration of rituximab is associated with unsatisfactory response of first-line R-CHOP treatment in patients with follicular lymphoma with grade 1/2." Acta Pharmacologica Sinica (2020): 1-7.	Institute of Clinical Pharmacology, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006, China.	RIT-FD-RM
Choi, So Yoon, et al. "Potential Utility of Therapeutic Drug Monitoring of Adalimumab in Predicting Short-Term Mucosal Healing and Histologic Remission in Pediatric Crohn's Disease Patients." Journal of Korean Medical Science 35.16 (2020).	Department of Pediatrics, Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea	ADA-FD-HUM ADA-QLS-HUM
González García, Jonathan, et al. "Pharmacokinetics of Trastuzumab After Subcutaneous and Intravenous Administration in Obese Patients." Annals of Pharmacotherapy (2020): 1060028020902318.	Complejo Hospitalario Universitario de Canarias, Santa Cruz de Tenerife, La Laguna, Spain.	TRA-FD-HH
de Redín, Inés Luis, et al. "In vivo efficacy of bevacizumab-loaded albumin in the treatment of colorectal cancer." Drug Delivery and Translational Research (2020): 1-11.	Department of Chemistry and Pharmaceutical Technology, NANO-VAC Research Group, University of Navarra, Pamplona, Spain.	BEV-FD-AA
Abe, Kazuki, et al. "Quantitative LC-MS/MS method for nivolumab in human serum using IgG purification and immobilized tryptic digestion." Analytical Methods 12.1 (2020): 54-62.	Department of Hospital Pharmacy, Hamamatsu University School of Medicine,1-20-1 Handayama, Higashi-ku, Hamamatsu 431-3192, Japan	NIV-FD-OPD
Zhang, Jinhua, et al. "Synthetic sRNA-based Engineering of Escherichia coli for Enhanced Production of Full-length Immunoglobulin G." Biotechnology Journal (2020): 1900363.	Frontier Science Center for Synthetic Biology and Key Laboratory of Systems Bioengineering (MOE), School of Chemical Engineering and Technology Tianjin University, Tianjin 300350, P. R. China	CET-FD-ERB
Flanagan, E., et al. "Stability of serum concentrations of infliximab and adalimumab across pregnancy in IBD." JOURNAL OF CROHNS & COLITIS. Vol. 13. GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND: OXFORD UNIV PRESS, 2019.	St Vincent's Hospital, Gastroenterology, Melbourne, Australia	ADA-FD-HUM INF-FD-REMI
Puente-Massaguer, Eduard, et al. "A statistical approach to improve compound screening in cell culture media." Engineering in Life Sciences 19.4 (2019): 315-327.	Departament d'Enginyeria Química, Biològica i Ambiental, Campus Bellaterra, Cerdanyola del Vallès, Universitat Autònoma de Barcelona, Barcelona, Spain	TRA-FD-HH
Choi, So Yoon, Ben Kang, and Yon Ho Choe. "Serum Infliximab Cutoff Trough Level Values for Maintaining Hematological Remission in Pediatric Inflammatory Bowel Disease." Gut and liver (2019).	Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul	INF-FD-REMI
González-García, J., et al. "Long-term stability of trastuzumab in plasma and whole blood samples stored under different conditions." Farmacia hospitalaria: organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 43.2 (2019): 50-52.	Servicio de Farmacia, Complejo Hospitalario Universitario de Canarias, San Cristóbal de La Laguna, Tenerife. Spain	TRA-FD-HH
Llabot, Juan M., et al. "In vitro characterization of new stabilizing albumin nanoparticles as a potential topical drug delivery system in the treatment of corneal neovascularization (CNV)." Journal of Drug Delivery Science and Technology 52 (2019): 379-385.	UNITEFA – CONICET, Facultad de Ciencias Químicas (FCQ-UNC). Córdoba, Argentina	BEV-FD-AA
Sureda, Manuel, et al. "Therapeutic drug monitoring of nivolumab in clinical practice: Preliminary experience." DEVELOPMENTAL IMMUNOTHERAPY AND TUMOR IMMUNOBIOLOGY (2019)	Plataforma de Oncología, Hospital Quironsalud Torrevieja. 03184 Torrevieja (Alicante), España.	NIV-FD-OPD

发表文章

Zapater, Pedro, et al. "Actual Anti-TNF Trough Levels Relate to Serum IL-10 in Drug-Responding Patients With Crohn's Disease." Inflammatory bowel diseases (2019).	Servicio de Farmacología Clínica, Hospital General Universitario de Alicante, Alicante, Spain.	ADA-FD-HUM INF-FD-REMI ADA-QLS-HUM INF-QLS-HUM
Vasudevan, Abhinav, et al. "Higher Mucosal Healing with Tumor Necrosis Factor Inhibitors in Combination with Thiopurines Compared to Methotrexate in Crohn's Disease." Digestive diseases and sciences (2018): 1-10.	Department of Gastroenterology and Hepatology, Eastern Health, Box Hill Hospital, Australia	ADA-FD-HUM INF-FD-REMI
Kang, Ben, et al. "Infliximab Trough Levels Are Associated With Mucosal Healing During Maintenance Treatment With Infliximab in Paediatric Crohn's Disease." Journal of Crohn's and Colitis (2018).	Department of Pediatrics, School of Medicine, Kyungpook National University, Daegu, South Korea	INF-FD-REMI INF-QNS-REMI
Bálint, Anita, et al. "Infliximab biosimilar CT-P13 therapy is effective in maintaining endoscopic remission in ulcerative colitis–results from multicentre observational cohort." Expert opinion on biological therapy just-accepted (2018).	Department of Medicine , University of Szeged , Szeged , Hungary.	INF-FD-REMI INF-QNS-REMI
González García, Jonathan, et al. "Influence of anthropometric characteristics in patients with Her2-positive breast cancer on initial plasma concentrations of trastuzumab." Annals of Pharmacotherapy 51.11 (2017): 976-980.	Complejo Hospitalario Universitario de Canarias (Santa Cruz de Tenerife), La Laguna, Spain	TRA-FD-HH
Kang, Ben, et al. "Long-term Outcomes After Switching to CT-P13 in Pediatric-Onset Inflammatory Bowel Disease: A Single-Center Prospective Observational Study." Inflammatory bowel diseases 24.3 (2018): 607-616.	Department of Pediatrics, Kyungpook National University School of Medicine, Daegu, Republic of Korea	INF-FD-REMI
Duricova, Dana, et al. "Safety of Anti-TNF-Alpha Therapy During Pregnancy on Long-term Outcome of Exposed Children: A Controlled, Multicenter Observation." Inflammatory bowel diseases (2018).	IBD Clinical and Research Center, ISCARE IVF, a.s., Prague, Czech Republic	INF-FD-REMI ADA-FD-HUM
Gregoritza, Manuel, et al. "Fabrication of antibody-loaded microgels using microfluidics and thiol-ene photoclick chemistry." European Journal of Pharmaceutics and Biopharmaceutics 127 (2018): 194-203.	Department of Pharmaceutical Technology, Faculty of Chemistry and Pharmacy, University of Regensburg, 93040 Regensburg, Germany.	BEV-FD-AA
de Redín, Inés Luis, et al. "Human serum albumin nanoparticles for ocular delivery of bevacizumab." International journal of pharmaceutics 541.1-2 (2018): 214-223.	Department of Pharmacy and Pharmaceutical Technology, NANO-VAC Research Group, University of Navarra, Spain	BEV-FD-AA
Pérez, Irene, et al. "Reliability evaluation of four different assays for therapeutic drug monitoring of infliximab levels." Therapeutic Advances in Gastroenterology 11 (2018): 1756284818783613.	Inflammatory Bowel Disease Unit, Department of Gastroenterology, Hospital Clínico San Carlos, Madrid, Spain	INF-FD-REMI INF-QLS-REMI
Bolia, Rishi, et al. "Secondary Loss of Response to Infliximab in Pediatric Crohn Disease: Does It Matter How and When We Start?." Journal of pediatric gastroenterology and nutrition 66.4 (2018): 637-640.	Department of Gastroenterology Royal Children's Hospital Melbourne Parkville, Avustralya	INF-FD-REMI
Kang, Ben, et al. "Subtherapeutic infliximab trough levels and complete mucosal healing are associated with sustained clinical remission after infliximab cessation in paediatric-onset Crohn's disease patients treated with combined immunosuppressive therapy." Journal of Crohn's and Colitis 12.6 (2018): 644-652.	Department of Pediatrics, Kyungpook National University School of Medicine, Daegu, Korea	INF-FD-REMI INF-QLS-REMI
Shirai, Shimpei, et al. "Immunogenicity of Quadrivalent Influenza Vaccine for Patients with Inflammatory Bowel Disease Undergoing Immunosuppressive Therapy." Inflammatory bowel diseases 24.5 (2018): 1082-1091.	Departments of Internal Medicine and Gastrointestinal Endoscopy, Faculty of Medicine, Saga University, Saga City, Saga, Japan.	ADA-FD-HUM
Iwamoto, Noriko, Akinobu Hamada, and Takashi Shimada. "Antibody drug quantitation in coexistence with anti-drug antibodies on nSMOL bioanalysis." Analytical biochemistry 540 (2018): 30-37.	Leading Technology of Bioanalysis and Protein Chemistry, SHIMADZU Corporation, Kuwabara-cho, Nishino-kyo, Nakagyo-ku, Kyoto 604-8511, Japan	TRA-FD-HH
Sugita, Naoko, et al. "Efficacy of a concomitant elemental diet to reduce the loss of response to adalimumab in patients with intractable Crohn's disease." Journal of gastroenterology and hepatology 33.3 (2018): 631-637.	Department of Gastroenterology, Osaka City University Graduate School of Medicine, Osaka, Japan.	ADA-FD-HUM
M. Kolar et al., "Pregnancy outcomes in women with inflammatory bowel disease treated with biosimilar infliximab" Gastroent Hepatol (2018) 72(1): 20-26	IBD Clinical and Research Centre, Prague,Czech Republic	INF-FD-REMI

发表文章

Jing Chen et. al., "Tailor-Making Fluorescent Hyaluronic Acid Microgels via Combining Microfluidics and Photoclick Chemistry for Sustained and Localized Delivery of Herceptin in Tumor." ACS Appl. Mater. Interfaces, (2018).	Biomedical Polymers Laboratory, and Jiangsu Key Laboratory of Advanced Functional Polymer Design and Application, College of Chemistry, Chemical Engineering and Materials Science, Soochow University, Suzhou 215123, People's Republic of China	TRA-FD-HH
Beswick, Lauren, et al. "Exploration of predictive biomarkers of early infliximab response in acute severe colitis: A prospective pilot study." Journal of Crohn's and Colitis 12.3 (2017): 289-297.	Department of Gastroenterology, Alfred Health and Monash University, Melbourne, Australia	INF-FD-REMI
Piñero, Paula, et al. "IL26 modulates cytokine response and anti-TNF consumption in Crohn's disease patients with bacterial DNA." Journal of Molecular Medicine 95.11 (2017): 1227-1236.	CIBERehd, Instituto de Salud Carlos III, Madrid, Spain.	INF-FD-REMI ADA-FD-HUM
Štefan Raffáč et al., "Detection of anti-infliximab antibodies in Slovak IBD patients and its costs saving effect" Neuroendocrinology Letters Volume 38 Suppl. 1 (2017)	Department of laboratory medicine, Louis Pasteur University Hospital, Košice, Slovakia	INF-FD-REMI INF-QNS-REMI
Ward, M. G., et al. "Intra-patient variability in adalimumab drug levels within and between cycles in Crohn's disease." Alimentary pharmacology & therapeutics 45.8 (2017): 1135-1145.	Department of Gastroenterology, Alfred Hospital, Melbourne, Vic., Australia.	ADA-FD-HUM
Kevin H, et al, "Prolonged in vivo expression and anti-tumor response of DNA-based anti-HER2 antibodies": Oncotarget, 2018, Vol. 9, (No. 17), pp: 13623-13636.	Laboratory for Therapeutic and Diagnostic Antibodies, KU Leuven – University of Leuven, Leuven B-3000, Belgium	TRA-FD-HH
Aomori, Tohru, et al. "Suppression of infliximab antibody levels by azathioprine in patients with rheumatoid arthritis." Die Pharmazie-An International Journal of Pharmaceutical Sciences 72.2 (2017): 95-97.	Division of Pharmaceutical Care Sciences, Center for Social Pharmacy and Pharmaceutical Care Sciences, Faculty of Pharmacy, Keio University, 1-5-30 Shibakoen, Minato-ku, Tokyo 105-8521, Japan	INF-FD-REMI INF-QNS-REMI
Kaito Shibata, et al. Simple and rapid LC-MS/MS method for the absolute determination of cetuximab in human serum using an immobilized trypsin. Journal of Pharmaceutical and Biomedical Analysis Volume 146, Pages 266-272, 30 November 2017	Department of Hospital Pharmacy, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-ku, Hamamatsu, Shizuoka 431-3192, Japan	CET-FD-ERB
Johannes Gojo, Robert Sauermann, Ursula Knaack, Irene Slave, Andreas Peyrl, Pharmacokinetics of Bevacizumab in Three Patients Under the Age of 3 Years with CNS Malignancies. Drugs R D 17:469-474, 2017.	Department of Pediatrics, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria	BEV-FD-AA
Ohem J, Hradsky O, Zarubova K, Copova I, Bukovska P, Prusa R, Malickova K and Bronsky J. Evaluation of Infliximab Therapy in Children with Crohn's Disease Using Trough Levels Predictors. Dig Dis. Aug 18, 2017.	Gastroenterology and Nutrition Unit, Department of Paediatrics, Prague, Czech Republic	INF-FD-REMI INF-QNS-REMI
Al-Karkhi MA, Al-Ani MM, Jassim NA, Mahdi BM, Association Between HLA-DRB1 alleles and development of antibodies to infliximab in Iraqi patients with rheumatoid arthritis, Basic Research Journals, 6(3): 30-35, 2017.	Department of Microbiology and Immunology, Baquba Teaching Hospital.	INF-QNS-REMI
Bálint A, Rutka M, Végh Z, et al. Frequency and Characteristics of Infusion Reactions during Biosimilar Infliximab Treatment in Inflammatory Bowel Diseases: results from Central European nationwide cohort, Expert Opinion on Drug Safety, 16(8):885-890, 2017.	First Department of Medicine, University of Szeged, Szeged, Hungary;	INF-FD-REMI INF-QLS-REMI
Lombardi S, Bernardoni C, Bertolucci D, et al. Biologic therapies in rheumatic diseases: drug and anti-drug antibody levels and clinical efficacy. Journal of Autoimmunity and Cell Responses, 4(1), 2017.	SSD Clinical Analysis and Immunoallergology, Massa Carrara, Italy	ETA-FD-ENB
Gregoritza M, Messmann V, Abstiens K, Brandl FP, Göpferich AM, Controlled antibody release from degradable thermoresponsive hydrogels cross-linked by Diels-Alder chemistry, Biomacromolecules, Just Accepted Manuscript, 2017.	Department of Pharmaceutical Technology, Faculty of Chemistry and Pharmacy, University of Regensburg, 93040 Regensburg, Germany	BEV-FD-AA
Aldrich MB, Velasquez FC, Kwon S, Lymphatic delivery of etanercept via nanotopography improves response to collagen-induced arthritis, et al., Arthritis Research & Therapy 19:116, 2017.	The Center for Molecular Imaging, The Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center, Houston, TX 77030, USA	ETA-FD-ENB
Kolar M, Duricova D, Bortlik M, et al., Infliximab Biosimilar (Remsima TM) in Therapy of Inflammatory Bowel Diseases Patients: Experience from One Tertiary Inflammatory Bowel Diseases Centre, Digestive Disease, 35:91–100, 2017.	a IBD Clinical and Research Centre, ISCARE, Prague, Czech Republic	INF-FD-REMI INF-QLS-REMI

发表文章

Gibellini L, De Biasi S, Bianchini E, et al. Anti-TNF-α Drugs Differently Affect the TNFα-sTNFR System and Monocyte Subsets in Patients with Psoriasis. Richard Y, ed. PLoS ONE. 11(12), 2016	Department of Surgery, Medicine, Dentistry and Morphological Sciences, University of Modena and Reggio Emilia, Modena, Italy	ETA-FD-ENB ETA-QLS-ENB INF-FD-REMI INF-QLS-REMI ADA-FD-HUM ADA-QLS-HUM
Julsgaard M, Christensen LA, Gibson PR, Bell SJ. Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on Infection. Gastroenterology. Jul;151(1):110-9, 2016.	Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus C, Denmark.	INF-FD-REMI ADA-FD-HUM
Jonathan GG, Beatriz AÁ, Nazco C GJ, Norberto BL, Fernando GN. Plasma levels of trastuzumab in gastric cancer: Case report. J Oncol Pharm Pract. Sep 23, 2016.	Pharmacy, Complejo Hospitalario Universitario de Canarias, San Cristo´bal de La Laguna, Santa Cruz de Tenerife, Spain	TRA-FD-HH
Choi SY, Kang B, Lee JH, Choe YH. Clinical Use of Measuring Trough Levels and Antibodies against Infliximab in Patients with Pediatric Inflammatory Bowel Disease. Gut Liver, 2016.	Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul	INF-FD-REMI INF-QNS-REMI
Chen L., et al., Efficient Production of a Bioactive Bevacizumab Monoclonal Antibody Using the 2A Self-cleavage Peptide in Transgenic Rice Callus. Frontiers in Plant Science, 7 (1156), 2016.	School of Life Sciences, Sun Yat-sen University, Guangzhou, China	BEV-FD-AA
Kang B., et al., Mucosal Healing in Paediatric Patients with Moderate-to-Severe Luminal Crohn's Disease Under Combined Immunosuppression: Escalation versus Early Treatment	Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea	INF-QNS-REMI
Farkas K., et al., Efficacy of infliximab biosimilar CT-P13 induction therapy on mucosal healing in ulcerative colitis. Journal of Crohn's and Colitis Advance Access published, 2016.	Department of Medicine, University of Szeged, Szeged, Hungary	INF-FD-REMI INF-QLS-REMI
Gutiérrez A, Zapater P, Francés R. Gut Bacterial DNA Translocation is an Independent Risk Factor of Flare at Short Term in Patients with Crohn's Disease. Am J Gastroenterol.,111(4):529-40, 2016.	Servicio de Medicina Digestiva, Hospital General Universitario de Alicante, Alicante, Spain.	ADA-FD-HUM INF-FD-REMI ADA-QLS-HUM INF-QLS-HUM
Won Jae Song, Ben Kang, So Yoon Choi, and Yon Ho Choe. Adalimumab Treatment in Pediatric-Onset Crohn's Disease Patients after Infliximab Failure: A Single Center Study. Pediatr Gastroenterol Hepatol Nutr.; 19(2): 116–122, 2016.	Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea	INF-QLS-REMI
Hayashi S, et al., Early Prognostic Factors Associated with the Efficacy of Infliximab Treatment for Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate. Rheumatol Ther., 3:155–166, 2016.	Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan	INF-FD-REMI
Kui R, Gál B, Gaál M, Kiss M, Kemény L1, Gyulai R. Presence of antidrug antibodies correlates inversely with the plasma tumor necrosis factor (TNF)-α level and the efficacy of TNF-inhibitor therapy in psoriasis. J Dermatol.,43(9):1018-23, 2016.	IBD Clinical and Research Centre, Iscare a.s., Prague, Czech Republic,	INF-FD-REMI ADA-FD-HUM
Al-Karkhi M.A., et al., Correlation between Anti-infliximab and Anti-CCP Antibodies Development in Patients with Rheumatoid Arthritis Treated with Infliximab in Baghdad Teaching Hospital. IOSR Journal of Dental and Medical Sciences, 14(11) : 95-100, 2015.	Department of Microbiology & Immunology, College of medicine, University of Baghdad	INF-QLS-REMI
Bodini G., Edoardo G. Giannini, Edoardo V. Savarino, and Vincenzo Savarino. Adalimumab Trough Levels and Response to Biological Treatment in Patients With Infl ammatory Bowel Disease: A Useful Cutoff in Clinical Practice. Am J Gastroenterol., Vol.110, 2015.	Gastroenterology Unit, Department of Internal Medicine, IRCCS-Azienda Ospedaliera Universitaria San Martino-IST, University of Genoa, Genoa, Italy.	ADA-FD-HUM
Juanola O., et al., Anti-TNF-alpha loss of response is associated with a decreased percentage of FoxP3+ T cells and a variant NOD2 genotype in patients with Crohn's disease. J Gastroenterol,50:758–768, 2015.	CIBERehd, Instituto de Salud Carlos III, Madrid, Spain.	ADA-FD-HUM INF-FD-REMI ADA-QLS-HUM INF-QLS-REMI
Fujita T, Murata Y, Hemmi S, Kajiwara M, Yabuki M, et al. (2015) Persistent Complement Activation is Associated with Insulin Resistance and Chronic Inflammation in Overweight Patients with Type 2 Diabetes with Dyslipidemia. Int J Immunol Immunother 2:007, 2015.	Department of Nephrology, Hypertension and Endocrinology, Nihon University School of Medicine, Japan	Q-TNF-α
Malíckova K, et al., Serum trough infliximab levels: A comparison of three different immunoassays for the monitoring of CT-P13 (infliximab) treatment in patients with inflammatory bowel disease, Biologicals 2015.	Institute of Medical Biochemistry and Laboratory Diagnostics, 1st Medical Faculty and General Teaching Hospital, Charles University, Prague, Czech Republic.	INF-FD-REMI

发表文章

Lee Y.M. et al, Infliximab "Top-Down" Strategy is Superior to "Step-Up" in Maintaining Long-Term Remission in the Treatment of Pediatric Crohn Disease. JPGN 60: (737–743), 2015.	Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine,Goyang, South Korea	INF-QNS-REMI
Al-Karkhi M.A., et al., Development of Antibodies against Infliximab in Iraqi Patients with Rheumatoid Arthritis. J Fac Med Baghdad, 57: (241-243), 2015	Dept. of Microbiology &Immunology, college of medicine, University of Baghdad	INF-QLS-REMI
Bergen T.V., et al., Complementary effects of bevacizumab and MMC in the improvement of surgical outcome after glaucoma filtration surgery. Acta Ophthalmologica, 667-678, 2015.	Laboratory of Ophthalmology, KU Leuven, Leuven, Belgium	BEV-FD-AA
Aydın C, Ataoğlu H., Demonstration of β-1,2 Mannan Structures Expressed on the Cell Wall of Candida albicans Yeast Form But Not on the Hyphal Form by Using Monoclonal Antibodies Mikrobiyol Bul 49(1): 66-76, 2015.	Ankara Üniversitesi Biyoteknoloji Enstitüsü, Ankara, Türkiye	mAb-ACMK-1
Kozub P, Curkova AK, Zuzulova M, Simaljakova M, Management of Infliximab Treated Patients with Psoriasis Based On Infliximab Plasma Levels and Antibodies to Infliximab, Clinical & Experimental Dermatology Research, 5(2), 2014.	Department of Dermatology and Venerology, Comenius University Faculty of Medicine, Bratislava, Slovakia,	INF-FD-REMI INF-QNS-REMI
Pallagi-Kunstár É. et al., Utility of serum TNF-a, infliximab trough level, and antibody titers in inflammatory bowel disease. World J Gastroenterol. 20(17): (5031-5035), 2014.	Department of Medicine, University of Szeged, H6720 Szeged, Hungary	INF-FD-REMI INF-QNS-REMI Q-TNF-α
Khanna R., et al., Therapeutic Drug Monitoring of TNF Antagonists in Inflammatory Bowel Disease. Gastroenterology & Hepatology, (478-489),2014.	Department of Medicine at the University of Western Ontario in London, Ontario, Canada.	ADA-FD-HUM
Krajcovicova A. et al., Delayed hypersensitivity reaction after initial dose of infliximab: a case report. European Journal of Gastroenterology& Hepatology, 26:(485-487), 2014.	Gastroenterology Unit, Department of Internal Medicine V., University Hospital Bratislava, Bratislava, Slovakia.	INF-FD-REMI INF-QNS-REMI
Erdemli Ö, et al, In vitro evaluation of effects of sustained anti-TNF release from MPEG-PCL-MPEG and PCL microspheres on human rheumatoid arthritis synoviocytes.2014. Journal of Biomaterials Application, 29(4):524-42, 2014.	Department of Engineering Sciences, Middle East Technical University, Ankara, Turkey	ETA-FD-ENB
Avdeeva A.A., Aleksandrova E.N., Karateev D.E., Luchikhina E.L., Novikov A.A., Cherkasova M.V., Nasonov E.L. Efficacy Of Adalimumab In Early Rheumatoid Arthritis In Relation To Its Serum Level And The Presence Of Anti-Drug Antibody, Rheumatology Science and Practice, 52(6):624-630, 2014.	V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia	ADA-FD-HUM ADA-QLS-HUM
Bortlik M, et al, Impact of Anti-Tumor Necrosis Factor Alpha Antibodies Administered to Pregnant Women With Inflammatory Bowel Disease on Long-term Outcome of Exposed Children. Inflamm Bowel Dis 20 : (495-451), 2014.	IBD Clinical and Research Centre, ISCARE, Charles University, Prague, Czech Republic	INF-FD-REMI AD-FD-HUM
Jung Y et al., "Temperature-modulated noncovalent interaction controllable complex for the long-term delivery of etanercept to treat rheumatoid arthritis", J. Control. Release 2013.	Department of Biotechnology, The Catholic University of Korea, 43 Jibong-ro, Wonmi-gu, Bucheon-si, Gyeonggi-do 420-743, Republic of Korea.	ETA-FD-ENB
Gutierrez A, et al, Genetic susceptibility to increased bacterial translocation influences the response to biological therapy in patients with Crohn's disease, Gut 0:1–9, 2013	Servicio de MedicinaDigestiva, Hospital General Universitario de Alicante, Alicante, Spain	ADA-FD-HUM INF-FD-REMI ADA-QLS-HUM INF-QLS-REMI
Grosen A., et al, Infliximab concentrations in the milk of nursing mothers with inflammatory bowel disease, J Crohns Colitis 2013.	Dept. of Hepatology and Gastroenterology, AarhusUniversity Hospital, Denmark	INF-FD-REMI
Romero G., et al, Poly(Lactide-co-Glycolide) Nanoparticles, Layer by Layer Engineered for the Sustainable Delivery of AntiTNF-α. Macromol. Biosci. 13: (903–912), 2013.	CIC biomaGUNE, Paseo Miramón 182 C, 20009 San Sebastian, Gipuzkoa, Spain.	ADA-FD-HUM
Cheong C, et al, Etanercept Attenuates Traumatic Brain Injury in Rats by Reducing Brain TNF-α Contents and by Stimulating Newly Formed Neurogenesis, Mediators of Inflammation, 2013; Volume 2013, Article ID 620837, 9 pages **	Department of Biotechnology, Southern Taiwan University of Science and Technology, Tainan, Taiwan	ETA-FD-ENB
Bortlik M et al, "Pregnancy and newborn outcome of mothers with inflammatory bowel diseases exposed to anti-TNF-a therapy during pregnancy: three-center study", Scandinavian Journal of Gastroenterology. 48: 951–958, 2013.	IBD Clinical and Research Centre, ISCARE, Charles University, Prague, Czech Republic.	INF-FD-REMI AD-FD-HUM

发表文章

Bodini G, Savarino V, Fazio V, et al. Relationship Between Drug Serum Concentration and Clinical Activity in Patients With Crohn Disease Who Achieved Remission With Adalimumab – a Prospective Study,Aga, Volume 142, Issue 5, Supplement 1, Page S-388, 2012.	Gastrointestinal Unit, Department of Internal Medicine, University of Genoa, Genoa, Italy.	ADA-FD-HUM ADA-QNS-HUM
Bortlik M, et al, Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease, Journal of Crohn's and Colitis, 2012.	IBD Clinical and Research Centre, ISCARE a.s., 1st Faculty of Medicine, Charles University in Prague, Czech Republic	INF-QNS-REMI
Malickova K, et al, Phosphatidylserine-dependent anti-prothrombin antibodies (aPS/PT) in infliximab-treated patients with inflammatory bowel diseases, Autoimmun Highlights, 2012.	Laboratory of Clinical Immunology and Allergology,Institute of Medical Biochemistry and Laboratory Diagnostics, 1st Faculty of Medicine and General University Hospital, Charles University in Prague, Karlovo na´me˘stı´ 32, 121 11 Prague 2, Czech Republic	INF-QNS-REMI
Takahashi H, et al, Plasma trough levels of adalimumab and infliximab in terms of clinical efficacy during the treatment of psoriasis, Journal of Dermatology, 39: 1- 4, 2012.	Department of Dermatology, Asahikawa Medical University, Asahikawa, Japan	AD-QLS-HUM INF-QLS-REMI
Seok Lee Y, et al, "Efficacy of Early Infliximab Treatment for Pediatric Crohn's Disease: A Three-year Follow-up", Pediatric Gastroenterology, Hepatology & Nutrition, 15(4):243-249, 2012.	Department of Pediatrics, Samsung Medical Center, School of Medicine, Sungkyunkwan University, Seoul	INF-QLS-REMI
Molnar T, et al, "Importance of trough levels and antibody titers on the efficacy and safety of Infliximab therapy in inflammatory bowel disease", Z Gastroenterol, 50 - A53, 2012.	First Department of Medicine, University of Szeged, Szeged, Hungary	INF-FD-REMI INF-QNS-REMI
Kato S, et al, "Elevated Serum IgE Prior to Acute Severe Infusion Reaction During Infliximab Maintenance Therapy in a Crohn's Disease Patient", Crohn's & Colitis Foundation of America, 2011.	Department of Gastroenterology and Hepatology, Saitama Medical Centre, Saitama Medical University, Saitama, Japan	INF-QNS-REMI
Adisen E, et al, "Anti-infliximab antibody status and its relation to clinical response in psoriatic patients": A pilot study, Journal of Dermatology, 37: 708–713, 2010.	Department of Dermatology, Gazi University, Faculty of Medicine, Ankara, Turkey.	INF-QLS-REMI
Pękala, Anna, Rafał Filip, and David Aebisher. "Anti-drug antibodies in patients with inflammatory bowel diseases treated with biosimilar infliximab: A prospective cohort study." Journal of Clinical Medicine 10.12 (2021): 2653.	Department of Gastroenterology, IBD Unit of Clinical Hospital, Rzeszow, Poland	INF-QNS-REMS
Hollevoet, Kevin, et al. "Bridging the clinical gap for DNA-based antibody therapy through translational studies in sheep." Human Gene Therapy 30.11 (2019): 1431-1443.	Laboratory for Therapeutic and Diagnostic Antibodies, KU Leuven, University of Leuven, Belgium	TRA-FD-HH
Sakane, Hideo, et al. "Anti-drug antibodies and rheumatoid factor level in patients with rheumatoid arthritis using the infliximab biosimilar CT-P13." BMC rheumatology 6.1 (2022): 1-5.	Department of Orthopaedic Surgery, Gunma University Graduate School of Medicine, 3-39-22, Showamachi, Maebashi, Gunma 371-8511, Japan	INF-QNS-REMI
Rentsch, Clarissa A., et al. "Pharmacist-Driven Therapeutic Infliximab Monitoring at the Point Of Care Using Rapidly Assessed Drug Levels In Patients with Inflammatory Bowel Disease." Therapeutic Drug Monitoring (2022): 10-1097.	Department of Gastroenterology Alfred Health and Central Clinical School, Monash University. Melbourne, Australia	INF-FD-REMI
Golshani, Maryam, et al. "SARS-CoV-2 Specific Humoral Immune Responses after BNT162b2 Vaccination in Hospital Healthcare Workers." Vaccines 10.12 (2022): 2038.	Institute of Immunology and Microbiology, First Faculty of Medicine, Charles University, 121 08 Prague, Czech Republic	COR-QNS-IGG-S1 COR-QNS-IGM-S1
Maspero, Marianna, et al. "S79 Long Term Outcomes of Straight Ileoanal Anastomoses Converted to Ileal Pouch Anal Anastomoses." Official journal of the American College of Gastroenterology| ACG 117 (2022): S21.	Cleveland Clinic Foundation, Cleveland, Ohio, United States	INF-FD-REMI INF-QNS-REMI
Maffei Svobodová, Ludmila, et al. "Multidisciplinární spolupráce při výzkumu stanovení hladin protilátek IgG a IgM u onemocnění COVID 19." (2022).	Institute of Biophysics and Informatics, 1. Faculty of Medicine, Charles University, Prague, Czech	COR-QNS-IGG-SRBD COR-QNS-IGM-SRBD
POSTERS		
Choi, So Yoon, et al. "Potential Utility of Therapeutic Drug Monitoring of Adalimumab in Predicting Short-Term Mucosal Healing and Histologic Remission in Pediatric Crohn's Disease Patients." Journal of Korean Medical Science 35.17 (2020).	Department of Pediatrics, Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea	ADA-FD-HUM ADA-QLS-HUM
Little, R., et al. "P709 Is there a difference in adalimumab drug levels according to pen vs. syringe use: An international, multi-centre retrospective analysis." Journal of Crohn's and Colitis 12.supplement_1 (2018): S469-S470.	Alfred Health and Monash University, Gastroenterology, Melbourne, Australia,	AD-FD-HUM

发表文章

García Gil S, Ramos Díaz R., ANÁLISIS DE LA CONCENTRACIONES PLASMÁTICAS DE NIVOLUMAB EN EL TRATAMIENTO DEL CPNM	Servicio de Farmacia. Complejo Hospitalario Universitario de Canarias, La Laguna (Tenerife)	NIV-FD-OPD
H. Akbulut, M. Ocal et al., The trough levels of bevacizumab significantly affects the outcome of the treatment in patents with metastatic colorectal cancer: A Turkish Oncology Group Study	Medical Oncology, Ankara University School of Medicine, Ankara Oncology Hospital, School of Medicine. Ankara, TR	BEV-QNS-AA
Patil A, Upadhyaya SK, Dawar R, et al., Through Infiliximab Levels and Anti-Infiliximab Antibodies in Spondyloarthritis Patients on Treatment with Low Dose Infiliximab: A Single Centre Cross-Sectional Study, BMJ Journals, Annals of the Rheumatic Diseases,(2017).	Rheumatology; Microbiology, Indraprastha Apollo Hospitals, Delhi, India	INF-FD-REMI INF-QNS-REMI
Malickova K, Duricova D , Kolar M, et al., No difference in immunogenicity of the original and biosimilar infliximab in patients with inflammatory bowel disease: short-term results, First Medical Faculty and General Teaching Hospital, Charles University, Institute of Medical Biochemistry and Laboratory Diagnostics, Prague, Czech Republic, 2 ISCARE, IBD clinical and research centre, Prague, Czech Republic, (2017).	Clinical and Research Center for Inflammatory Bowel Disease, ISCARE a.s, Prague, Czech Republic.	INF-QLS-REMI
H. Akbulut, et al: The role of immune system on the efficacy of bevacizumab in patients with metastatic colorectal cancer (mCRC). Annals of Oncology, Volume 27, 2016, 7–11 October 2016, Copenhagen, Denmark.	Medical Oncology, Ankara University School of Medicine, Ankara, Turkey.	BEV-QNS-AA
Perez I, Fernandez L, Sanchez-Ramón S, P551 Comparison of 4 assay kits for measuring infliximab trough levels and antibodies to infliximab in patients with inflammatory bowel disease,Hospital Clínico San Carlos, IBD Unit, Madrid, Spain, Hospital Clínico San Carlos, Clinical Immunology, IdiSSC, IBD Unit, Gastroenterology,2016 Madrid, Spain.	Hospital Clínico San Carlos, IBD Unit, Madrid, Spain	INF-FD-REMI
Goldberg R., et al, Predictors of sub-therapeutic infliximab oradalimumab trough levels and anti-drug antibodies and their influence on therapeutic decisions, ECCO 2014 Inflammatory Bowel Disease.	Monash University, Monash Health, Dept. of Gastroenterology, Melbourne, Australia	ADA-FD-HUM INF-FD-REMI
Julsgaard M., et al, Intra-uterine Exposure to Anti-TNF-alpha therapy (ERA study):Infliximab and adalimumab cord blood levels correlate with maternal levels at birth, ECCO 2014 Inflammatory Bowel Disease.	Aarhus University Hospital, Department of Hepatology and Gastroenterology, Aarhus, Denmark	ADA-QNS-HUM
Szepes Z., et al, Clinical utility of measuring serum TNF alpha level, anti TNF alpha levels and antibody titers in critical situations in inflammatory bowel disease and in psoriasis, ECCO 2014 Inflammatory Bowel Disease.	University of Szeged, First Department of Medicine, Szeged, Hungary	ADA-FD-HUM INF-FD-REMI ADA-QLS-HUM INF-QLS-REMI
Julsgaard M, et al, Time since last drug exposure in pregnancy determines Adalimumab and Infliximab levels in neonates(Era Study), Italy 2014.	Aarhus University Hospital, Department of Hepatology and Gastroenterology, Aarhus, Denmark	ADA-QNS-HUM
Bodini G, et al, Correlation between Adalimumab trough serum concentration, Anti-Adalimumab antibodies and TNF-Alpha levels with clinical outcome in patients affected by Crohn's disease,. United European Gastroenterology. Italy 2013.	Gastroenterology Unit, Department of Internal Medicine, IRCCS-Azienda Ospedaliera Universitaria San Martino-IST, University of Genoa, Genoa, Italy.	ADA-FD-HUM ADA-QLS-HUM
Duricova D, et al, Predictors of sustained response to infliximab with Crohn's disease: A single cohort study, Czech Republic	4th Department of Internal Medicine, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.	INF-FD-REMI
Lukas M, et al, Anti-infliximab antibodies in routine clinical practice is it worth to assess them, Czech Republic	PIGMOD Center, Laboratory of Cell Regeneration and Plasticity, Institute of Animal Physiology and Genetics, Czech Academy of Sciences, Libechov, Czech Republic.	INF-QLS-REMI
Malickova K, et al, Relationship between serum trough infliximab levels, serum antibodies to infliximab, serum albumin levels and clinical response to infliximab treatment in patients with inflammatory bowel diseases, Charles University in Prague Czech Republic. (2011)	Institute of Clinical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine of Charles University and General University Hospital, Prague, Czech Republic	IPI-QLS-YER
Malickova K, et al, Formation of antiphospholipid antibodies and antibodies to infliximab in anti-TNF-alpha antibody-treated patients with inflammatory bowel diseases, Charles University in Prague Czech Republic (2011).	Institute of Clinical Biochemistry and Laboratory Diagnostics, 1st Faculty of Medicine and General University Hospital, Charles University in Prague, Czech Republic	INF-FD-REMI INF-QNS-REMI
Malickova K, et al,. Monitoring patients treated with infliximab: Assessing Anti-Infliximab antibodies, Czech Republic. EUROMEDLAB. Autoimmune diseases 2009. S115	Institute of Clinical Biochemistry and Laboratory Diagnostics, General Teaching Hospital and 1st Faculty of Medicine of Charles University, Prague, Czech Republic	INF-QLS-REMI

发表文章

THESIS		
Evaluación de la relación exposición-respuesta de bevacizumab y de cetuximab en cáncer colorrectal metastásico y de cetuximab en cáncer de cabeza y cuello Silvia Peña Cabia	UNIVERSIDAD COMPLUTENSE DE MADRID, Madrid, Spain	CET-FD-ERB BEV-FD-AA
TNF-α antagonist attenuates systemic lipopolysaccharide-induced brain white matter injury in neonatal rats Shin, Seung Han, M.D.	National University, Seoul, Korea	ETA-FD-ENB
A BIOLÓGIAI TERÁPIA HATÉKONYSÁGA ÉS KORLÁTAI KÜLÖNBÖZŐ TÍPUSÚ GYULLADÁSOS BÉLBETEGSÉGEKBEN Dr. Molnár Tamás	Szegedi Tudományegyetem	Q-TNF-α INF-FD-REMI INF-QNS-REMI
A PIKKELYSÖMÖR KLINIKAI, BIOKÉMIAI, IMMUNOLÓGIAI ÉS GENETIKAI JELLEGZETESSÉGEINEK VIZSGÁLATA Dr. Gyulai Rolland	Pécsi Tudományegyetem, ÁOK	Q-TNF-α INF-FD-REMI INF-QLS-REMI
La Spectrometrıe De Masse Appliquee A La Quantıfıcatıon Absolue Des Antıcorps Monoclonaux Therapeutıques En Mılieu Plasmatıque Pour La Realısatıon D'etudes Pharmacocınetıques Pharmacodynamıques Dr.Rachel LEGERON-LIEUTENANT	Universitè de Bordeaux, France	BEV-FD-AA
EVALUATION of TRANSSCLERAL PERMEABILITY EFFECTS of NANOTECHNOLOGY BASED DRUG DELIVERY SYSTEM in OCULAR DRUG APPLICATIONS Dr. NAGİHAN UĞURLU	Hacettepe University	BEV-FD-AA
INVESTIGATION OF THE PATHOMECHANISM OF DIARRHOEA-RELATED DISEASES Dr. ÉVA PALLAGI	University of Szeged	Q-TNF-α INF-FD-REMI INF-QNS-REMI
Radiomarcaje y biodistribución mediante SPECT-CT de nanopartículas de seroalbúmina humana con bevacizumab Dr. ROCÍO RAMOS MEMBRIVE	Universidad de Navarra	BEV-FD-AA
ASOCIACIÓN ENTRE EL PERFIL DE CITOCINAS PRO-INFLAMATORIAS, LOS EVENTOS INMUNOGÉNICOS Y LA ACTIVIDAD CLÍNICA EN PACIENTES CON ARTRITIS REUMATOIDE TRATADOS CON INFLIXIMAB Y ADALIMUMAB Q.F.B. EMMANUEL ANTONIO ORTIZ SALDIVAR	UNIVERSIDAD AUTÓNOMA DEL ESTADO DE MORELOS	AD-FD-HUM ADA-QLS-HUM
Nanoparticle and Macromolecular Transfer across the Human Placental Barrier, Michael Gruber MSc. BSc. Medical University of Graz, Department of Obstetrics and Gynaecology	Department of Obstetrics and Gynaecology, Medical University of Graz, Graz, Austria	TRA-FD-HH DEN-FD-PRO
CRUCIAL STEPS FOR TREATMENT OPTIMIZATION AND DECISION MAKING IN INFLAMMATORY BOWEL DISEASE MANAGEMENT. Szántó, Kata Judit	Department of Medicine, Albert Szent-Györgyi Medical School University of Szeged Szeged, Hungary	ADA-FD-HUM INF-FD-REMI
PATENTS		
Imaging probe for angiogenic activity in pulmonary arterial hypertension Paul B. YuMarcelo DICARLI	THE BRIGHAM AND WOMEN'S HOSPITAL, INC. MASSACHUSETTS, USA	BEV-FD-AA
CONTROLED DRUG DELIVERY SYSTEMS FOR ANTI-TNF-α Aysen TEZCANER Dilek Keskin Seza OZEN Bulent ATILLA Ali USANMAZ Cetin KOCAEFE Ozge ERDEMLI	ODTÜ MÜHENDİSLİK BİLİMLERİ BÖLÜMÜ, ANKARA	ETA-FD-ENB
The plant source recombinant humanized shellfish of a kind of optimization cuts down preparation method and the medical applications of monoclonal antibody,	CHINA	BEV-FD-AA
Genetically modified micro-organ secreting antibody and methods of use Reem MiariNir ShapirInbal ZAFIR-LAVIE	MEDGENETICS MEDICAL ISRAEL LTD., Misgav, Israel	TRA-FD-HH

Matriks Biotek

生物药物ELISA试剂盒，

药物检测中的佼佼者！

Matriks Biotek公司成立于2002年，专门生产针对抗体药的ELISA试剂盒，用于检测抗体药的体内浓度或因使用抗体药而产生的抗体的体内浓度。Matriks Biotek产品达到ISO 13485 & CE IVD标准。目前，在30个国家有超过25个的大型制药企业都在使用其产品。

Matriks 中国区总代理：艾美捷科技

400-6800-868

www.amyjet.com

MATRIKS BIOTEK

20 years experience

innovation for health & wellness

CE IVD